41859-67-0 | Bezafibrate

Packsize	Purity	Availability	Price	Discounted Price
1g	98%	in stock	$15.00	$10.00
5g	98%	in stock	$18.00	$12.00
25g	98%	in stock	$58.00	$40.00
100g	98%	in stock	$216.00	$151.00
500g	98%	in stock	$756.00	$529.00

Description

• Catalog Number: AB71110
• Chemical Name: Bezafibrate
• CAS Number: 41859-67-0
• Molecular Formula: C19H20ClNO4
• Molecular Weight: 361.8194
• MDL Number: MFCD00078970
• SMILES: Clc1ccc(cc1)C(=O)NCCc1ccc(cc1)OC(C(=O)O)(C)C
• NSC Number: 758174

Computed Properties

• Complexity: 452
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 25
• Hydrogen Bond Acceptor Count: 4
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 7
• XLogP3: 3.8

Literature

• Expression of cytochrome P450 epoxygenases and soluble epoxide hydrolase is regulated by hypolipidemic drugs in dose-dependent manner.

  Toxicology and applied pharmacology 20180915

• Amelioration of free fatty acid-induced fatty liver by quercetin-3-O-β-D-glucuronide through modulation of peroxisome proliferator-activated receptor-alpha/sterol regulatory element-binding protein-1c signaling.

  Hepatology research : the official journal of the Japan Society of Hepatology 20160201

• Metabolism of methiocarb and carbaryl by rat and human livers and plasma, and effect on their PXR, CAR and PPARα activities.

  The Journal of toxicological sciences 20160101

• Identification of modulators of the nuclear receptor peroxisome proliferator-activated receptor α (PPARα) in a mouse liver gene expression compendium.

  PloS one 20150101

• Phthalates efficiently bind to human peroxisome proliferator activated receptor and retinoid X receptor α, β, γ subtypes: an in silico approach.

  Journal of applied toxicology : JAT 20140701

• PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells.

  Toxicology and applied pharmacology 20140401

• A correlation between the in vitro drug toxicity of drugs to cell lines that express human P450s and their propensity to cause liver injury in humans.

  Toxicological sciences : an official journal of the Society of Toxicology 20140101

• Novel PPAR pan agonist, ZBH ameliorates hyperlipidemia and insulin resistance in high fat diet induced hyperlipidemic hamster.

  PloS one 20140101

• Stimulation of rat liver branched-chain alpha-keto acid dehydrogenase activity by low doses of bezafibrate.

  Toxicology 20130405

• Identification of old drugs as potential inhibitors of HIV-1 integrase - human LEDGF/p75 interaction via molecular docking.

  Journal of molecular modeling 20121201

• Bezafibrate lowers very long-chain fatty acids in X-linked adrenoleukodystrophy fibroblasts by inhibiting fatty acid elongation.

  Journal of inherited metabolic disease 20121101

• Inhibition of NF-κB activation by 4-hydroxynonenal contributes to liver injury in a mouse model of alcoholic liver disease.

  The American journal of pathology 20121101

• Environmental optimization of continuous flow ozonation for urban wastewater reclamation.

  The Science of the total environment 20121015

• Synthesis of highly water-soluble fibrate derivatives via BGLation.

  Bioorganic & medicinal chemistry letters 20121015

• Omega-3 fatty acids enhance monocyte-suppressing effect of bezafibrate in patients with isolated hypertriglyceridemia.

  European journal of internal medicine 20121001

• Simvastatin but not bezafibrate decreases plasma lipoprotein-associated phospholipase A₂ mass in type 2 diabetes mellitus: relevance of high sensitive C-reactive protein, lipoprotein profile and low-density lipoprotein (LDL) electronegativity.

  European journal of internal medicine 20121001

• Effects of effluent organic matter characteristics on the removal of bulk organic matter and selected pharmaceutically active compounds during managed aquifer recharge: Column study.

  Journal of contaminant hydrology 20121001

• Bezafibrate can be a new treatment option for mitochondrial fatty acid oxidation disorders: evaluation by in vitro probe acylcarnitine assay.

  Molecular genetics and metabolism 20120901

• Hemostatic effects of omega-3 fatty acids in isolated hypertriglyceridemic patients treated with bezafibrate.

  European journal of internal medicine 20120901

• Use of fibrates in clinical practice: Queensland Lipid Group consensus recommendations.

  International journal of evidence-based healthcare 20120901

• Detection of bioavailable peroxisome proliferator-activated receptor gamma modulators by a cell-based luciferase reporter system.

  Analytical biochemistry 20120815

• Peroxisome proliferator-activated receptor α (PPARα) activation advances locomotor activity and feeding daily rhythms in mice.

  International journal of obesity (2005) 20120801

• Binding of bezafibrate to human serum albumin: insight into the non-covalent interaction of an emerging contaminant with biomacromolecules.

  Molecules (Basel, Switzerland) 20120604

• Automated capillary electrophoresis with on-line preconcentration by solid phase extraction using a sequential injection manifold and contactless conductivity detection.

  Analytica chimica acta 20120521

• In vivo antihyperlipidemic activity of a new series of N-(benzoylphenyl) and N-(acetylphenyl)-1-benzofuran-2-carboxamides in rats.

  Archiv der Pharmazie 20120501

• In situ assay of fatty acid β-oxidation by metabolite profiling following permeabilization of cell membranes.

  Journal of lipid research 20120501

• Simulation study of instrumental variable approaches with an application to a study of the antidiabetic effect of bezafibrate.

  Pharmacoepidemiology and drug safety 20120501

• The pharmacokinetics and hepatic disposition of repaglinide in pigs: mechanistic modeling of metabolism and transport.

  Molecular pharmaceutics 20120402

• Occurrence and removal of pharmaceuticals in wastewater treatment plants at the Spanish Mediterranean area of Valencia.

  Chemosphere 20120401

• Sodium butyrate stimulates expression of fibroblast growth factor 21 in liver by inhibition of histone deacetylase 3.

  Diabetes 20120401

• Anti-inflammatory and PPAR transactivational effects of secondary metabolites from the roots of Asarum sieboldii.

  Bioorganic & medicinal chemistry letters 20120401

• Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington's disease.

  Human molecular genetics 20120301

• Antihypercholesterolaemic influence of dietary tender cluster beans (Cyamopsis tetragonoloba) in cholesterol fed rats.

  The Indian journal of medical research 20120301

• Relationship between paraoxonase and homocysteine: crossroads of oxidative diseases.

  Archives of medical science : AMS 20120227

• Effect of bezafibrate treatment on late-onset mitochondrial myopathy in mice.

  Human molecular genetics 20120201

• The cardiovascular effects of peroxisome proliferator-activated receptor agonists.

  The American journal of medicine 20120201

• Novel approach to meta-analysis of microarray datasets reveals muscle remodeling-related drug targets and biomarkers in Duchenne muscular dystrophy.

  PLoS computational biology 20120201

• Various oscillation patterns of serum fibroblast growth factor 21 concentrations in healthy volunteers.

  Diabetes & metabolism journal 20120201

• Prevalence of Dyslipidemia among Korean Adults: Korea National Health and Nutrition Survey 1998-2005.

  Diabetes & metabolism journal 20120201

• Bezafibrate for primary biliary cirrhosis.

  The Cochrane database of systematic reviews 20120118

• Acute and chronic saturated fatty acid treatment as a key instigator of the TLR-mediated inflammatory response in human adipose tissue, in vitro.

  The Journal of nutritional biochemistry 20120101

• Hypertriglyceridemia, Metabolic Syndrome, and Cardiovascular Disease in HIV-Infected Patients: Effects of Antiretroviral Therapy and Adipose Tissue Distribution.

  International journal of vascular medicine 20120101

• Toxicity of mixtures of perfluorooctane sulphonic acid with chlorinated chemicals and lipid regulators.

  Chemosphere 20120101

• Nifedipine prevents hepatic fibrosis in a non-alcoholic steatohepatitis model induced by an L-methionine-and choline-deficient diet.

  Molecular medicine reports 20120101

• Lipoprotein lipase as a candidate target for cancer prevention/therapy.

  Biochemistry research international 20120101

• Differential induction of stearoyl-CoA desaturase 1 and 2 genes by fibrates in the liver of rats.

  Biological & pharmaceutical bulletin 20120101

• Relaxation of rat thoracic aorta by fibrate drugs correlates with their potency to disturb intracellular calcium of VSMCs.

  Vascular pharmacology 20120101

• PPARs in Regulation of Paraoxonases: Control of Oxidative Stress and Inflammation Pathways.

  PPAR research 20120101

• Potent PPARα activator derived from tomato juice, 13-oxo-9,11-octadecadienoic acid, decreases plasma and hepatic triglyceride in obese diabetic mice.

  PloS one 20120101

• [Focal myositis as a side effect of antilipidemics - 2 patients with involvement of the forearm].

  Handchirurgie, Mikrochirurgie, plastische Chirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft fur Handchirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft fur Mikrochirurgie der Peripheren Nerven und Gefasse : Organ der V... 20120101

• Pioglitazone decreases hepatitis C viral load in overweight, treatment naïve, genotype 4 infected-patients: a pilot study.

  PloS one 20120101

• Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT study.

  Cardiovascular diabetology 20120101

• The association of hypertriglyceridemia with cardiovascular events and pancreatitis: a systematic review and meta-analysis.

  BMC endocrine disorders 20120101

• Exploring the molecular basis of antifungal synergies using genome-wide approaches.

  Frontiers in microbiology 20120101

• Some commonly used brominated flame retardants cause Ca2+-ATPase inhibition, beta-amyloid peptide release and apoptosis in SH-SY5Y neuronal cells.

  PloS one 20120101

• Comparative transcriptional network modeling of three PPAR-α/γ co-agonists reveals distinct metabolic gene signatures in primary human hepatocytes.

  PloS one 20120101

• Copper and bezafibrate cooperate to rescue cytochrome c oxidase deficiency in cells of patients with SCO2 mutations.

  Orphanet journal of rare diseases 20120101

• Development of an inflammation-associated colorectal cancer model and its application for research on carcinogenesis and chemoprevention.

  International journal of inflammation 20120101

• Apolipoprotein E gene polymorphism: effects on plasma lipids and risk of type 2 diabetes and coronary artery disease.

  Cardiovascular diabetology 20120101

• Cardiovascular events in patients received combined fibrate/statin treatment versus statin monotherapy: Acute Coronary Syndrome Israeli Surveys data.

  PloS one 20120101

• Fenofibrate enhances the in vitro differentiation of foxp3(+) regulatory T cells in mice.

  PPAR research 20120101

• Anti-inflammatory effect of simvastatin in an experimental model of spinal cord trauma: involvement of PPAR-α.

  Journal of neuroinflammation 20120101

• Conditional Expression of Human PPARδ and a Dominant Negative Variant of hPPARδ In Vivo.

  PPAR research 20120101

• Structural insights into human peroxisome proliferator activated receptor delta (PPAR-delta) selective ligand binding.

  PloS one 20120101

• Assessment of the effect of periodontal treatment in patients with coronary artery disease : A pilot survey.

  Journal of cardiovascular disease research 20120101

• Red carpeting the newer antidiabetics.

  Journal of pharmacology & pharmacotherapeutics 20120101

• PPARs: Interference with Warburg' Effect and Clinical Anticancer Trials.

  PPAR research 20120101

• Endogenous bioactive peptides as potential biomarkers for atherosclerotic coronary heart disease.

  Sensors (Basel, Switzerland) 20120101

• VLDL triglycerides inhibit HDL-associated paraoxonase 1 (PON1) activity: in vitro and in vivo studies.

  BioFactors (Oxford, England) 20120101

• The Current Knowledge of the Role of PPAR in Hepatic Ischemia-Reperfusion Injury.

  PPAR research 20120101

• PPARα Activation Protects against Anti-Thy1 Nephritis by Suppressing Glomerular NF-κB Signaling.

  PPAR research 20120101

• Peroxisome proliferator-activated receptorα agonists differentially regulate inhibitor of DNA binding expression in rodents and human cells.

  PPAR research 20120101

• Pan-PPAR Agonist, Bezafibrate, Restores Angiogenesis in Hindlimb Ischemia in Normal and Diabetic Rats.

  International journal of peptides 20120101

• Fenofibrate inhibited the differentiation of T helper 17 cells in vitro.

  PPAR research 20120101

• Delayed-type hypersensitivity to fenofibrate.

  Journal of investigational allergology & clinical immunology 20120101

• Bezafibrate for X-linked adrenoleukodystrophy.

  PloS one 20120101

• Long-term bezafibrate treatment improves skin and spleen phenotypes of the mtDNA mutator mouse.

  PloS one 20120101

• Induction of 1-acylglycerophosphocholine acyltransferase genes by fibrates in the liver of rats.

  Biological & pharmaceutical bulletin 20120101

• Accumulation of pharmaceuticals, Enterococcus, and resistance genes in soils irrigated with wastewater for zero to 100 years in central Mexico.

  PloS one 20120101

• How peroxisomes affect aflatoxin biosynthesis in Aspergillus flavus.

  PloS one 20120101

• Removal of pharmaceutical residue in municipal wastewater by DAF (dissolved air flotation)-MBR (membrane bioreactor) and ozone oxidation.

  Water science and technology : a journal of the International Association on Water Pollution Research 20120101

• Occurrence of pharmaceuticals and endocrine disruptors in raw sewage and their behavior in UASB reactors operated at different hydraulic retention times.

  Water science and technology : a journal of the International Association on Water Pollution Research 20120101

• Species differences in the effects of bezafibrate as a potential treatment of mitochondrial disorders.

  Cell metabolism 20111207

• Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).

  PLoS computational biology 20111201

• Elongation of the Fe-His bond in the α subunit induced by binding of the allosteric effector bezafibrate to hemoglobins.

  The journal of physical chemistry. B 20111110

• A metabolic shift induced by a PPAR panagonist markedly reduces the effects of pathogenic mitochondrial tRNA mutations.

  Journal of cellular and molecular medicine 20111101

• Protective effects of L-type fatty acid-binding protein (L-FABP) in proximal tubular cells against glomerular injury in anti-GBM antibody-mediated glomerulonephritis.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20111101

• The effect of bezafibrate and omega-3 fatty acids on lymphocyte cytokine release and systemic inflammation in patients with isolated hypertriglyceridemia.

  European journal of clinical pharmacology 20111101

• Bezafibrate restores the inhibition of FSH-induced follicular development and steroidogenesis by tumor necrosis factor-alpha through peroxisome proliferator-activated receptor-gamma pathway in an in vitro mouse preantral follicle culture.

  Biology of reproduction 20111101

• PPARγ activation induces acute PAI-1 gene expression in the liver but not in adipose tissues of diabetic model mice.

  Thrombosis research 20111101

• Bezafibrate upregulates carnitine palmitoyltransferase II expression and promotes mitochondrial energy crisis dissipation in fibroblasts of patients with influenza-associated encephalopathy.

  Molecular genetics and metabolism 20111101

• Role of biodegradation in the removal of pharmaceutically active compounds with different bulk organic matter characteristics through managed aquifer recharge: batch and column studies.

  Water research 20111015

• Supplementation of pyruvate prevents palmitate-induced impairment of glucose uptake in C2 myotubes.

  Molecular and cellular endocrinology 20111015

• Effect of bezafibrate on monocyte cytokine release and systemic inflammation in patients with impaired fasting glucose.

  Journal of clinical pharmacology 20111001

• Bezafibrate prevents palmitate-induced apoptosis in osteoblastic MC3T3-E1 cells through the NF-κB signaling pathway.

  International journal of molecular medicine 20111001

• Increases in mitochondrial biogenesis impair carcinogenesis at multiple levels.

  Molecular oncology 20111001

• Exposure to human pharmaceuticals Carbamazepine, Ibuprofen and Bezafibrate causes molecular effects in Dreissena polymorpha.

  Aquatic toxicology (Amsterdam, Netherlands) 20111001

• Benzyl 2-{4-[2-(4-chloro-benzoyl-amino)-eth-yl]phen-oxy}-2-methyl-propionate.

  Acta crystallographica. Section E, Structure reports online 20111001

• Antihyperlipidemic properties of novel N-(benzoylphenyl)-5-substituted-1H-indole-2-carboxamides in Triton WR-1339-induced hyperlipidemic rats.

  Molecules (Basel, Switzerland) 20110929

• Additive improvement induced by bezafibrate in patients with primary biliary cirrhosis showing refractory response to ursodeoxycholic acid.

  Journal of gastroenterology and hepatology 20110901

• Bezafibrate, a lipid-lowering pharmaceutical, as a potential endocrine disruptor in male zebrafish (Danio rerio).

  Aquatic toxicology (Amsterdam, Netherlands) 20110901

• No more pilots, a phase III trial of fibrates in primary biliary cirrhosis is long overdue!

  Journal of gastroenterology and hepatology 20110901

• The diagnosis and treatment of primary biliary cirrhosis.

  The Korean journal of hepatology 20110901

• Ciprofibrate quantification in human plasma by high-performance liquid chromatography coupled with electrospray tandem mass spectrometry for pharmacokinetic studies.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20110815

• Reactive tracer test to evaluate the fate of pharmaceuticals in rivers.

  Environmental science & technology 20110801

• Effects of bezafibrate in nonalcoholic steatohepatitis model mice with monosodium glutamate-induced metabolic syndrome.

  European journal of pharmacology 20110715

• In vivo correction of COX deficiency by activation of the AMPK/PGC-1α axis.

  Cell metabolism 20110706

• Monocyte-suppressing effect of bezafibrate but not omega-3 fatty acids in patients with isolated hypertriglyceridaemia.

  Basic & clinical pharmacology & toxicology 20110701

• Comparison of effects of bezafibrate and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 and adipocytokine levels in dyslipidemic subjects with impaired glucose tolerance or type 2 diabetes mellitus: results from a crossover study.

  Atherosclerosis 20110701

• Regulation of proprotein convertase subtilisin/kexin type 9: therapeutical perspectives.

  Atherosclerosis 20110701

• Activation of peroxisome proliferator-activated receptor-α (PPARα) suppresses postprandial lipidemia through fatty acid oxidation in enterocytes.

  Biochemical and biophysical research communications 20110624

• Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management.

  European heart journal 20110601

• Capsaicin attenuates palmitate-induced expression of macrophage inflammatory protein 1 and interleukin 8 by increasing palmitate oxidation and reducing c-Jun activation in THP-1 (human acute monocytic leukemia cell) cells.

  Nutrition research (New York, N.Y.) 20110601

• Impact of bezafibrate and atorvastatin on lipoprotein subclass in patients with type III hyperlipoproteinemia: result from a crossover study.

  Clinica chimica acta; international journal of clinical chemistry 20110512

• Activation of peroxisome proliferator-activated receptor-alpha stimulates both differentiation and fatty acid oxidation in adipocytes.

  Journal of lipid research 20110501

• Pretreatment by low-dose fibrates protects against acute free fatty acid-induced renal tubule toxicity by counteracting PPARα deterioration.

  Toxicology and applied pharmacology 20110501

• Solid-phase treatment with the fungus Trametes versicolor substantially reduces pharmaceutical concentrations and toxicity from sewage sludge.

  Bioresource technology 20110501

• Bezafibrate enhances proliferation and differentiation of osteoblastic MC3T3-E1 cells via AMPK and eNOS activation.

  Acta pharmacologica Sinica 20110501

• Dehydroepiandrosterone (DHEA) replacement decreases insulin resistance and lowers inflammatory cytokines in aging humans.

  Aging 20110501

• Fate of organic micropollutants in the hyporheic zone of a eutrophic lowland stream: results of a preliminary field study.

  The Science of the total environment 20110415

• Fenofibrate suppresses microvascular inflammation and apoptosis through adenosine monophosphate-activated protein kinase activation.

  Metabolism: clinical and experimental 20110401

• Metabolic manipulators: a well founded strategy to combat mitochondrial dysfunction.

  Journal of inherited metabolic disease 20110401

• Occurrence and behavior of non-steroidal anti-inflammatory drugs and lipid regulators in wastewater and urban river water of the Pearl River Delta, South China.

  Journal of environmental monitoring : JEM 20110401

• Comparison of APPI, APCI and ESI for the LC-MS/MS analysis of bezafibrate, cyclophosphamide, enalapril, methotrexate and orlistat in municipal wastewater.

  Journal of mass spectrometry : JMS 20110401

• The causes and consequences of low levels of high density lipoproteins in patients with diabetes.

  Diabetes & metabolism journal 20110401

• Proteomic mapping of bezafibrate-treated human hepatocytes in primary culture using two-dimensional liquid chromatography.

  Toxicology letters 20110305

• Fibrate use in diabetes: new concepts.

  Journal of diabetes 20110301

• Stimulation of lipogenesis as well as fatty acid oxidation protects against palmitate-induced INS-1 beta-cell death.

  Endocrinology 20110301

• Mendelian randomization studies do not support a role for raised circulating triglyceride levels influencing type 2 diabetes, glucose levels, or insulin resistance.

  Diabetes 20110301

• Nutritional and metabolic status of HIV-positive patients with lipodystrophy during one year of follow-up.

  Clinics (Sao Paulo, Brazil) 20110301

• Hypoxia triggers major metabolic changes in AML cells without altering indomethacin-induced TCA cycle deregulation.

  ACS chemical biology 20110218

• Long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients with persistent elevated triglycerides.

  Cardiovascular drugs and therapy 20110201

• Effect of structurally constrained oxime-ether linker on PPAR subtype selectivity: Discovery of a novel and potent series of PPAR-pan agonists.

  Bioorganic & medicinal chemistry 20110115

• Toxicological evaluation of acyl glucuronides of nonsteroidal anti-inflammatory drugs using human embryonic kidney 293 cells stably expressing human UDP-glucuronosyltransferase and human hepatocytes.

  Drug metabolism and disposition: the biological fate of chemicals 20110101

• Possible Link between Metabolic Syndrome and Chronic Kidney Disease in the Development of Cardiovascular Disease.

  Cardiology research and practice 20110101

• Cleanup strategies and advantages in the determination of several therapeutic classes of pharmaceuticals in wastewater samples by SPE-LC-MS/MS.

  Analytical and bioanalytical chemistry 20110101

• Effects of clofibrate on salt loading-induced hypertension in rats.

  Journal of biomedicine & biotechnology 20110101

• Transforming Growth Factor-β1 as a Common Target Molecule for Development of Cardiovascular Diseases, Renal Insufficiency and Metabolic Syndrome.

  Cardiology research and practice 20110101

• 'The metabolic syndrome... is dead': these reports are an exaggeration.

  Cardiovascular diabetology 20110101

• Pharmacological and non-pharmacological interventions to influence adipose tissue function.

  Cardiovascular diabetology 20110101

• Adiponectin provides cardiovascular protection in metabolic syndrome.

  Cardiology research and practice 20110101

• Critical role of the Rb family in myoblast survival and fusion.

  PloS one 20110101

• The effects of diet-induced obesity on hepatocyte insulin signaling pathways and induction of non-alcoholic liver damage.

  International journal of general medicine 20110101

• The AOM/DSS murine model for the study of colon carcinogenesis: From pathways to diagnosis and therapy studies.

  Journal of carcinogenesis 20110101

• Vulnerability to oxidative stress in vitro in pathophysiology of mitochondrial short-chain acyl-CoA dehydrogenase deficiency: response to antioxidants.

  PloS one 20110101

• Dual acting and pan-PPAR activators as potential anti-diabetic therapies.

  Handbook of experimental pharmacology 20110101

• The role of high-density lipoproteins in reducing the risk of vascular diseases, neurogenerative disorders, and cancer.

  Cholesterol 20110101

• The peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate maintains bone mass, while the PPAR gamma agonist pioglitazone exaggerates bone loss, in ovariectomized rats.

  BMC endocrine disorders 20110101

• Mitochondria and PGC-1α in Aging and Age-Associated Diseases.

  Journal of aging research 20110101

• Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment.

  The open cardiovascular medicine journal 20110101

• Case of primary biliary cirrhosis-autoimmune hepatitis overlap which manifested after delivery.

  Internal medicine (Tokyo, Japan) 20110101

• Pleiotropic effects of glitazones: a double edge sword?

  Frontiers in pharmacology 20110101

• Mild Hypothermia Attenuates Intercellular Adhesion Molecule-1 Induction via Activation of Extracellular Signal-Regulated Kinase-1/2 in a Focal Cerebral Ischemia Model.

  Stroke research and treatment 20110101

• Thiazolidinediones are potent inducers of fibroblast growth factor 21 expression in the liver.

  Biological & pharmaceutical bulletin 20110101

• Plasma lipids and betaine are related in an acute coronary syndrome cohort.

  PloS one 20110101

• Changes in the 24 h Rhythmicity of Liver PPARs and Peroxisomal Markers When Feeding Is Restricted to Two Daytime Hours.

  PPAR research 20110101

• Clofibrate relaxes the longitudinal smooth muscle of the mouse distal colon through calcium-mediated desensitisation of contractile machinery.

  Pharmacology 20110101

• Hemostatic effects of bezafibrate and ω-3 fatty acids in isolated hypertriglyceridemic patients.

  Pharmacological reports : PR 20110101

• Potential role of differential medication use in explaining excess risk of cardiovascular events and death associated with chronic kidney disease: a cohort study.

  BMC nephrology 20110101

• Association between the interleukin-6 promoter polymorphism -174G/C and serum lipoprotein(a) concentrations in humans.

  PloS one 20110101

• Rhabdomyolysis associated with fenofibrate monotherapy in a patient with chronic myelogenous leukemia.

  Case reports in gastroenterology 20110101

• Prevalence, Predictors, and Impact of Low High-Density Lipoprotein Cholesterol on in-Hospital Outcomes Among Acute Coronary Syndrome Patients in the Middle East.

  The open cardiovascular medicine journal 20110101

• Long-term fenofibrate treatment impaired glucose-stimulated insulin secretion and up-regulated pancreatic NF-kappa B and iNOS expression in monosodium glutamate-induced obese rats: is that a latent disadvantage?

  Journal of translational medicine 20110101

• South Asian Consensus Guidelines for the rational management of diabetes in human immunodeficiency virus/acquired immunodeficiency syndrome.

  Indian journal of endocrinology and metabolism 20110101

• Screening for active small molecules in mitochondrial complex I deficient patient's fibroblasts, reveals AICAR as the most beneficial compound.

  PloS one 20110101

• Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin.

  Lipids in health and disease 20110101

• 13-hydroxy linoleic acid increases expression of the cholesterol transporters ABCA1, ABCG1 and SR-BI and stimulates apoA-I-dependent cholesterol efflux in RAW264.7 macrophages.

  Lipids in health and disease 20110101

• Allopurinol causing drug rash with eosinophilia and systemic symptoms syndrome: a challenging diagnosis.

  International journal of general medicine 20110101

• Cancer chemopreventive ability of conjugated linolenic acids.

  International journal of molecular sciences 20110101

• Skeletal effects of the saturated 3-thia Fatty Acid tetradecylthioacetic Acid in rats.

  PPAR research 20110101

• Peroxisome Proliferator-Activated Receptor-α Activation Decreases Mean Arterial Pressure, Plasma Interleukin-6, and COX-2 While Increasing Renal CYP4A Expression in an Acute Model of DOCA-Salt Hypertension.

  PPAR research 20110101

• PPAR-α Agonist Fenofibrate Upregulates Tetrahydrobiopterin Level through Increasing the Expression of Guanosine 5'-Triphosphate Cyclohydrolase-I in Human Umbilical Vein Endothelial Cells.

  PPAR research 20110101

• Hyperglycemia in apolipoprotein E-deficient mouse strains with different atherosclerosis susceptibility.

  Cardiovascular diabetology 20110101

• The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases.

  Journal of advanced pharmaceutical technology & research 20110101

• Effect of the metabolic syndrome and hyperuricemia on outcome in patients with coronary artery disease (from the Bezafibrate Infarction Prevention Study).

  The American journal of cardiology 20101215

• The hypolipidemic activity of novel benzofuran-2-carboxamide derivatives in Triton WR-1339-induced hyperlipidemic rats: a comparison with bezafibrate.

  Journal of enzyme inhibition and medicinal chemistry 20101201

• In vitro evaluation of inhibitory effects of antidiabetic and antihyperlipidemic drugs on human carboxylesterase activities.

  Drug metabolism and disposition: the biological fate of chemicals 20101201

• A predictive ligand-based Bayesian model for human drug-induced liver injury.

  Drug metabolism and disposition: the biological fate of chemicals 20101201

• [Oxidized low density lipoprotein and peroxisome proliferator-activated receptor α induced endogenous fibroblast growth factor 21 upregulation is protective against apoptosis in cardiac endothelial cells].

  Zhonghua xin xue guan bing za zhi 20101201

• Fibroblast growth factor 21 as a possible endogenous factor inhibits apoptosis in cardiac endothelial cells.

  Chinese medical journal 20101201

• Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.

  Lancet (London, England) 20101113

• Triglycerides and gallstone formation.

  Clinica chimica acta; international journal of clinical chemistry 20101111

• Effects of lipid-lowering drugs on adiponectin.

  Current vascular pharmacology 20101101

• Lycorine sensitizes CD40 ligand-protected chronic lymphocytic leukemia cells to bezafibrate- and medroxyprogesterone acetate-induced apoptosis but dasatanib does not overcome reported CD40-mediated drug resistance.

  Haematologica 20101101

• Disorders of muscle lipid metabolism: diagnostic and therapeutic challenges.

  Neuromuscular disorders : NMD 20101101

• Plasma apolipoprotein M responses to statin and fibrate administration in type 2 diabetes mellitus.

  Atherosclerosis 20101101

• Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.

  Bioorganic & medicinal chemistry letters 20101101

• Activation of PPARα by bezafibrate negatively affects de novo synthesis of sphingolipids in regenerating rat liver.

  Prostaglandins & other lipid mediators 20101101

• A tiered procedure for assessing the formation of biotransformation products of pharmaceuticals and biocides during activated sludge treatment.

  Journal of environmental monitoring : JEM 20101101

• Human health risk assessment of pharmaceuticals in water: issues and challenges ahead.

  International journal of environmental research and public health 20101101

• PPARα deficiency augments a ketogenic diet-induced circadian PAI-1 expression possibly through PPARγ activation in the liver.

  Biochemical and biophysical research communications 20101015

• Evaluation of zebrafish DNA integrity after exposure to pharmacological agents present in aquatic environments.

  Ecotoxicology and environmental safety 20101001

• Pathogenesis and treatment of mitochondrial myopathies: recent advances.

  Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology 20101001

• State of the art in muscle lipid diseases.

  Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology 20101001

• High-throughput identification of microbial transformation products of organic micropollutants.

  Environmental science & technology 20100901

• New treatments for chronic hepatitis C.

  The Korean journal of hepatology 20100901

• Synthesis and anti-hyperlipidemic evaluation of N‑(benzoylphenyl)-5-fluoro-1H-indole-2-carboxamide derivatives in Triton WR-1339-induced hyperlipidemic rats.

  Molecules (Basel, Switzerland) 20100826

• Comparative study of bezafibrate and pravastatin in patients with coronary artery disease and high levels of remnant lipoprotein.

  Circulation journal : official journal of the Japanese Circulation Society 20100801

• Fibrates: no ACCORD on their use in the treatment of dyslipidaemia.

  Current opinion in lipidology 20100801

• Relation of body mass index to mortality among men with coronary heart disease.

  The American journal of cardiology 20100801

• Response: effects of rosiglitazone on inflammation in Otsuka long-evans Tokushima Fatty rats (korean diabetes j 2010;34:191-9).

  Korean diabetes journal 20100801

• Bezafibrate for the treatment of primary sclerosing cholangitis.

  Journal of gastroenterology 20100701

• Bezafibrate induces plasminogen activator inhibitor-1 gene expression in a CLOCK-dependent circadian manner.

  Molecular pharmacology 20100701

• Bezafibrate mildly stimulates ketogenesis and fatty acid metabolism in hypertriglyceridemic subjects.

  The Journal of pharmacology and experimental therapeutics 20100701

• Long-term follow-up of bezafibrate treatment in patients with the myopathic form of carnitine palmitoyltransferase 2 deficiency.

  Clinical pharmacology and therapeutics 20100701

• Metabolic myopathies: the challenge of new treatments.

  Current opinion in pharmacology 20100601

• Neuropathy, retinopathy, and glucose-lowering treatments.

  Diabetes care 20100601

• Hypoglycemia, diabetes, and cardiovascular events.

  Diabetes care 20100601

• Activation of PPARalpha Attenuates IFNgamma and IL-1beta-induced Cell Proliferation in Astrocytes: Involvement of IL-6 Independent Pathway.

  The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology 20100601

• [Isolation of a bacterial strain capable of bezafibrate-degrading and biodegradation characteristics].

  Wei sheng wu xue bao = Acta microbiologica Sinica 20100601

• Inhibitory effect on hepatitis B virus in vitro by a peroxisome proliferator-activated receptor-gamma ligand, rosiglitazone.

  Biochemical and biophysical research communications 20100528

• Multi-residue analysis of pharmaceutical compounds in wastewaters by dual solid-phase microextraction coupled to liquid chromatography electrospray ionization ion trap mass spectrometry.

  Journal of chromatography. A 20100514

• Effect of heat stress and bezafibrate on mitochondrial beta-oxidation: comparison between cultured cells from normal and mitochondrial fatty acid oxidation disorder children using in vitro probe acylcarnitine profiling assay.

  Brain & development 20100501

• Efficacy of bezafibrate for chronic GVHD of the liver after allogeneic hematopoietic stem cell transplantation.

  Bone marrow transplantation 20100501

• Winter accumulation of acidic pharmaceuticals in a Swedish river.

  Environmental science and pollution research international 20100501

• Compared effects of missense mutations in Very-Long-Chain Acyl-CoA Dehydrogenase deficiency: Combined analysis by structural, functional and pharmacological approaches.

  Biochimica et biophysica acta 20100501

• Differing short-term neuroprotective effects of the fibrates fenofibrate and bezafibrate in MPTP and 6-OHDA experimental models of Parkinson's disease.

  Behavioural pharmacology 20100501

• Dynamics and attenuation of acidic pharmaceuticals along a river stretch.

  Environmental science & technology 20100415

• Combined bezafibrate and medroxyprogesterone acetate have efficacy without haematological toxicity in elderly and relapsed acute myeloid leukaemia (AML).

  British journal of haematology 20100401

• Bezafibrate and serum amyloid A--low-density lipoprotein complex in patients with type 2 diabetes mellitus and hypertriglyceridemia.

  European journal of internal medicine 20100401

• Mitochondrial quality control and neurological disease: an emerging connection.

  Expert reviews in molecular medicine 20100401

• Genome-wide association study of Lp-PLA(2) activity and mass in the Framingham Heart Study.

  PLoS genetics 20100401

• Impacts of different promoters on the mammalian one-hybrid assay for detecting nuclear receptor agonists.

  Analytical and bioanalytical chemistry 20100301

• Risk factors of drug interaction between warfarin and nonsteroidal anti-inflammatory drugs in practical setting.

  Journal of Korean medical science 20100301

• Combined therapy in the treatment of dyslipidemia.

  Fundamental & clinical pharmacology 20100201

• Bezafibrate induces myotoxicity in human rhabdomyosarcoma cells via peroxisome proliferator-activated receptor alpha signaling.

  Toxicology in vitro : an international journal published in association with BIBRA 20100201

• Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial.

  European heart journal 20100201

• Measuring hsCRP--an important part of a comprehensive risk profile or a clinically redundant practice?

  PLoS medicine 20100201

• Combination peroxisome proliferator-activated receptor gamma and alpha agonist treatment in Type 2 diabetes prevents the beneficial pioglitazone effect on liver fat content.

  Diabetic medicine : a journal of the British Diabetic Association 20100201

• Simultaneous determination of acidic, neutral and basic pharmaceuticals in urban wastewater by ultra high-pressure liquid chromatography-tandem mass spectrometry.

  Journal of chromatography. A 20100129

• Ecotoxicity assessment of lipid regulators in water and biologically treated wastewater using three aquatic organisms.

  Environmental science and pollution research international 20100101

• Occurrence of emerging pollutants in urban wastewater and their removal through biological treatment followed by ozonation.

  Water research 20100101

• The mitochondrial brain: From mitochondrial genome to neurodegeneration.

  Biochimica et biophysica acta 20100101

• Role of PPARs in Radiation-Induced Brain Injury.

  PPAR research 20100101

• Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors.

  European heart journal 20100101

• Bezafibrate treatment of primary biliary cirrhosis following incomplete response to ursodeoxycholic acid.

  Journal of clinical gastroenterology 20100101

• Validation of cell-based OATP1B1 assays to assess drug transport and the potential for drug-drug interaction to support regulatory submissions.

  Xenobiotica; the fate of foreign compounds in biological systems 20100101

• Evaluation of an hPXR reporter gene assay for the detection of aquatic emerging pollutants: screening of chemicals and application to water samples.

  Analytical and bioanalytical chemistry 20100101

• PPARs in Irradiation-Induced Gastrointestinal Toxicity.

  PPAR research 20100101

• Therapeutic effect of bezafibrate against biliary damage: a study of phospholipid secretion via the PPARalpha-MDR3 pathway.

  International journal of clinical pharmacology and therapeutics 20100101

• Hypertriglyceridemia: An underdiagnosed side effect of Capecitabine chemotherapy.

  Acta oncologica (Stockholm, Sweden) 20100101

• Safety and efficacy trial of adipose-tissue derived oral preparation V-6 Immunitor (V-6): results of open-label, two-month, follow-up study.

  Lipids in health and disease 20100101

• Role of PPAR-delta in the development of zymosan-induced multiple organ failure: an experiment mice study.

  Journal of inflammation (London, England) 20100101

• Rationale and design of the ADDITION-Leicester study, a systematic screening programme and randomised controlled trial of multi-factorial cardiovascular risk intervention in people with type 2 diabetes mellitus detected by screening.

  Trials 20100101

• Variations in atherosclerosis and remodeling patterns in aorta and carotids.

  Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance 20100101

• Peroxisome proliferator-activated receptor alpha (PPARalpha) agonists induce constitutive androstane receptor (CAR) and cytochrome P450 2B in rat primary hepatocytes.

  Drug metabolism and pharmacokinetics 20100101

• The PPARbeta/delta agonist GW0742 relaxes pulmonary vessels and limits right heart hypertrophy in rats with hypoxia-induced pulmonary hypertension.

  PloS one 20100101

• NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease.

  Lipids in health and disease 20100101

• Current status and future directions in lipid management: emphasizing low-density lipoproteins, high-density lipoproteins, and triglycerides as targets for therapy.

  Vascular health and risk management 20100101

• Inflammatory mediators of hepatic steatosis.

  Mediators of inflammation 20100101

• PPARalpha: energy combustion, hypolipidemia, inflammation and cancer.

  Nuclear receptor signaling 20100101

• FGF21 is dispensable for hypothermia induced by fasting in mice.

  Neuro endocrinology letters 20100101

• HPLC determination of bezafibrate in human plasma and its application to pharmacokinetics studies.

  Journal of chromatographic science 20100101

• Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia.

  Vascular health and risk management 20100101

• 'If it ain't broke, don't fix it': a commentary on the positive-negative results of the ACCORD Lipid study.

  Cardiovascular diabetology 20100101

• Fenofibrate in primary biliary cirrhosis: a pilot study.

  The open cardiovascular medicine journal 20100101

• Usefulness of bezafibrate for ovulation induction in clomiphene citrate-resistant polycystic ovary syndrome patients with dyslipidemia: a prospective pilot study of seven cases.

  Gynecologic and obstetric investigation 20100101

• Inborn errors of energy metabolism associated with myopathies.

  Journal of biomedicine & biotechnology 20100101

• Effect of bezafibrate on hepatic oxidative stress: comparison between conventional experimental doses and clinically-relevant doses in mice.

  Redox report : communications in free radical research 20100101

• PPARs in the Renal Regulation of Systemic Blood Pressure.

  PPAR research 20100101

• Molecular basis of a novel adaptation to hypoxic-hypercapnia in a strictly fossorial mole.

  BMC evolutionary biology 20100101

• Ipact of bezafibrate treatment in patients with hyperfibrinogenemia and ST-elevation acute myocardial infarction: a randomized clinical trial.

  Cirugia y cirujanos 20100101

• Evidence of direct smooth muscle relaxant effects of the fibrate gemfibrozil.

  Journal of smooth muscle research = Nihon Heikatsukin Gakkai kikanshi 20100101

• Synthesis and pharmacological evaluation of novel substituted and unsubstituted N-(benzoylphenyl)-1H-indole-2-carboxamides as potent antihypertriglyceridemic agents.

  Zeitschrift fur Naturforschung. C, Journal of biosciences 20100101

• Molecular Characterization of the Onset and Progression of Colitis in Inoculated Interleukin-10 Gene-Deficient Mice: A Role for PPARalpha.

  PPAR research 20100101

• Impact of medical therapy on atheroma volume measured by different cardiovascular imaging modalities.

  Cardiology research and practice 20100101

• Lipid disturbances in psoriasis: an update.

  Mediators of inflammation 20100101

• Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid.

  Vascular health and risk management 20100101

• Transport of pharmaceuticals in columns of a wastewater-irrigated Mexican clay soil.

  Journal of environmental quality 20100101

• Predictive performances of lipid accumulation product vs. adiposity measures for cardiovascular diseases and all-cause mortality, 8.6-year follow-up: Tehran lipid and glucose study.

  Lipids in health and disease 20100101

• The Role of PPARα Activation in Liver and Muscle.

  PPAR research 20100101

• PPARα in Obesity: Sex Difference and Estrogen Involvement.

  PPAR research 20100101

• PPARs in Rhythmic Metabolic Regulation and Implications in Health and Disease.

  PPAR research 20100101

• Bezafibrate induced increase in mitochondrial electron transport chain complex IV activity in human astrocytoma cells: Implications for mitochondrial cytopathies and neurodegenerative diseases.

  BioFactors (Oxford, England) 20100101

• Methods of chromatographic determination of medicines decreasing the level of cholesterol.

  Acta poloniae pharmaceutica 20100101

• PRIC295, a Nuclear Receptor Coactivator, Identified from PPARα-Interacting Cofactor Complex.

  PPAR research 20100101

• Peroxisome proliferator-activated receptor alpha target genes.

  PPAR research 20100101

• Gene Expression Profiling in Wild-Type and PPARα-Null Mice Exposed to Perfluorooctane Sulfonate Reveals PPARα-Independent Effects.

  PPAR research 20100101

• Effects of fenofibrate on lipid profiles, cholesterol ester transfer activity, and in-stent intimal hyperplasia in patients after elective coronary stenting.

  Lipids in health and disease 20100101

• A case of adolescent hyperlipoproteinemia with xanthoma and acute pancreatitis, associated with decreased activities of lipoprotein lipase and hepatic triglyceride lipase.

  Internal medicine (Tokyo, Japan) 20100101

• Lipid control and use of lipid-regulating drugs for prevention of cardiovascular events in Chinese type 2 diabetic patients: a prospective cohort study.

  Cardiovascular diabetology 20100101

• Low high-density lipoprotein cholesterol: current status and future strategies for management.

  Vascular health and risk management 20100101

• Leukocyte counts, myeloperoxidase, and pregnancy-associated plasma protein a as biomarkers for cardiovascular disease: towards a multi-biomarker approach.

  International journal of vascular medicine 20100101

• The role of fasting versus non-fasting triglycerides in ischemic stroke: a systematic review.

  Frontiers in neurology 20100101

• Uses and benefits of omega-3 ethyl esters in patients with cardiovascular disease.

  Journal of multidisciplinary healthcare 20100101

• Two siblings with familial chylomicronemia syndrome: disease course and effectiveness of early treatment.

  Case reports in medicine 20100101

• Fenofibrate treatment enhances antioxidant status and attenuates endothelial dysfunction in streptozotocin-induced diabetic rats.

  Experimental diabetes research 20100101

• Regulation of Proteome Maintenance Gene Expression by Activators of Peroxisome Proliferator-Activated Receptor α.

  PPAR research 20100101

• PPARs and xenobiotic-induced adverse effects: relevance to human health.

  PPAR research 20100101

• Effects of lipid-lowering pharmaceuticals bezafibrate and clofibric acid on lipid metabolism in fathead minnow (Pimephales promelas).

  Environmental toxicology and chemistry 20091201

• Improvement of nephrotic syndrome by intensive lipid-lowering therapy in a patient with lipoprotein glomerulopathy.

  Clinical and experimental nephrology 20091201

• Rhabdomyolysis associated with fibrate therapy: review of 76 published cases and a new case report.

  European journal of clinical pharmacology 20091201

• Phenoxy herbicides and fibrates potently inhibit the human chemosensory receptor subunit T1R3.

  Journal of medicinal chemistry 20091112

• Coupling of solid-phase microextraction with micellar desorption and high performance liquid chromatography for the determination of pharmaceutical residues in environmental liquid samples.

  Biomedical chromatography : BMC 20091101

• Triglycerides and HDL cholesterol: stars or second leads in diabetes?

  Diabetes care 20091101

• A reexamination of the PPAR-alpha activation mode of action as a basis for assessing human cancer risks of environmental contaminants.

  Environmental health perspectives 20091101

• Osthole, a potential antidiabetic agent, alleviates hyperglycemia in db/db mice.

  Chemico-biological interactions 20091030

• Regulation of CYP4A expression by bezafibrate in primary culture of rat and human hepatocytes: interspecies difference and influence of N-acetylcysteine.

  Toxicology in vitro : an international journal published in association with BIBRA 20091001

• Fibrates may cause an abnormal urinary betaine loss which is associated with elevations in plasma homocysteine.

  Cardiovascular drugs and therapy 20091001

• Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review.

  The American journal of medicine 20091001

• [65-year-old man with yellow-orange papules on both forearms. Eruptive xanthomas].

  Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete 20091001

• A clinical puzzle: fibrates and homocysteine elevation: editorial to: 'fibrates may cause an abnormal urinary betaine loss which is associated with elevations in plasma homocysteine' by M. Lever et al.

  Cardiovascular drugs and therapy 20091001

• Bisphenol A downregulates CYP19 transcription in JEG-3 cells.

  Toxicology letters 20090928

• Probing the fibrate binding specificity of rat liver fatty acid binding protein.

  Journal of medicinal chemistry 20090910

• Fenofibrate differentially regulates plasminogen activator inhibitor-1 gene expression via adenosine monophosphate-activated protein kinase-dependent induction of orphan nuclear receptor small heterodimer partner.

  Hepatology (Baltimore, Md.) 20090901

• Primary biliary cirrhosis.

  Seminars in immunopathology 20090901

• Cross-talk between vitamin D receptor (VDR)- and peroxisome proliferator-activated receptor (PPAR)-signaling in melanoma cells.

  Anticancer research 20090901

• Significance of inflammatory markers in diabetic patients with stable coronary artery disease.

  The Korean journal of internal medicine 20090901

• On the mechanism for PPAR agonists to enhance ABCA1 gene expression.

  Atherosclerosis 20090801

• Adaptability and selectivity of human peroxisome proliferator-activated receptor (PPAR) pan agonists revealed from crystal structures.

  Acta crystallographica. Section D, Biological crystallography 20090801

• Usefulness of combining serum uric acid and C-reactive protein for risk stratification of patients with coronary artery disease (Bezafibrate Infarction Prevention [BIP] study).

  The American journal of cardiology 20090715

• Fibrates in the treatment of cardiovascular risk and atherogenic dyslipidaemia.

  Current opinion in cardiology 20090701

• Eruptive xanthoma with unexpected granuloma annulare-like microscopic appearance: case report.

  Anais brasileiros de dermatologia 20090701

• Design, synthesis and hypolipidemic activity of novel 2-(m-tolyloxy) isobutyric acid derivatives.

  European journal of medicinal chemistry 20090601

• Effects of a methanolic fraction of soybean seeds on the transcriptional activity of peroxisome proliferator-activated receptors (PPAR).

  Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas 20090601

• Adenosine and adenosine receptors: Newer therapeutic perspective.

  Indian journal of pharmacology 20090601

• 15-deoxy-Delta(12,14)-prostaglandin J(2) inhibits fibrogenic response in human hepatoma cells.

  Toxicology letters 20090522

• Uncontrolled hypertriglyceridemia induced by capecitabine: case report and review of the literature.

  Cancer chemotherapy and pharmacology 20090401

• Bezafibrate at clinically relevant doses decreases serum/liver triglycerides via down-regulation of sterol regulatory element-binding protein-1c in mice: a novel peroxisome proliferator-activated receptor alpha-independent mechanism.

  Molecular pharmacology 20090401

• Antidiabetic action of bezafibrate in a large observational database.

  Diabetes care 20090401

• Rosiglitazone aggravates nonalcoholic Fatty pancreatic disease in C57BL/6 mice fed high-fat and high-sucrose diet.

  Pancreas 20090401

• Determination of bezafibrate, methotrexate, cyclophosphamide, orlistat and enalapril in waste and surface waters using on-line solid-phase extraction liquid chromatography coupled to polarity-switching electrospray tandem mass spectrometry.

  Journal of environmental monitoring : JEM 20090401

• Long-term benefit of high-density lipoprotein cholesterol-raising therapy with bezafibrate: 16-year mortality follow-up of the bezafibrate infarction prevention trial.

  Archives of internal medicine 20090309

• Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.

  Diabetes care 20090301

• Global sensitivity analysis for model-based prediction of oxidative micropollutant transformation during drinking water treatment.

  Water research 20090301

• Serum paraoxonase-I activity is unaffected by short-term administration of simvastatin, bezafibrate, and their combination in type 2 diabetes mellitus.

  European journal of clinical investigation 20090301

• Free-radical-induced oxidative and reductive degradation of fibrate pharmaceuticals: kinetic studies and degradation mechanisms.

  The journal of physical chemistry. A 20090219

• Bezafibrate for an inborn mitochondrial beta-oxidation defect.

  The New England journal of medicine 20090219

• Treatment of primary CLL cells with bezafibrate and medroxyprogesterone acetate induces apoptosis and represses the pro-proliferative signal of CD40-ligand, in part through increased 15dDelta12,14,PGJ2.

  Leukemia 20090201

• Activation of hepatic lipase expression by oleic acid: possible involvement of USF1.

  Nutrients 20090201

• Evaluation of the acute, chronic and teratogenic effects of a mixture of eleven pharmaceuticals on the cnidarian, Hydra attenuata.

  The Science of the total environment 20090115

• Elevated expression of osteopontin may be related to adipose tissue macrophage accumulation and liver steatosis in morbid obesity.

  Diabetes 20090101

• Comment on biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis.

  Hepatology (Baltimore, Md.) 20090101

• Effects of bezafibrate on dyslipidemia with cholestasis in children with familial intrahepatic cholestasis-1 deficiency manifesting progressive familial intrahepatic cholestasis.

  Metabolism: clinical and experimental 20090101

• Apolipoproteins and long-term prognosis in coronary heart disease patients.

  American heart journal 20090101

• Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial).

  The American journal of cardiology 20090101

• Metabolomic profiling of drug responses in acute myeloid leukaemia cell lines.

  PloS one 20090101

• Long-term effects of peroxisome proliferator-activated receptor ligand bezafibrate on N-terminal pro-B type natriuretic peptide in patients with advanced functional capacity impairment.

  Cardiovascular diabetology 20090101

• Role of MAPK in apolipoprotein CIII-induced apoptosis in INS-1E cells.

  Lipids in health and disease 20090101

• Optimization of an enzyme-linked immunosorbent assay to screen ligand of Peroxisome proliferator-activated receptor alpha.

  Immunopharmacology and immunotoxicology 20090101

• Pan-PPAR agonist beneficial effects in overweight mice fed a high-fat high-sucrose diet.

  Nutrition (Burbank, Los Angeles County, Calif.) 20090101

• Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)alpha agonist fenofibrate and the PPARgamma agonist pioglitazone.

  BMC endocrine disorders 20090101

• Peroxisome proliferator-activated receptors in HCV-related infection.

  PPAR research 20090101

• Time-dependent vascular effects of Endocannabinoids mediated by peroxisome proliferator-activated receptor gamma (PPARγ).

  PPAR research 20090101

• Suggestion for linkage of chromosome 1p35.2 and 3q28 to plasma adiponectin concentrations in the GOLDN Study.

  BMC medical genetics 20090101

• The independent relationship between triglycerides and coronary heart disease.

  Vascular health and risk management 20090101

• Dyslipidemia treatment of patients with diabetes mellitus in a US managed care plan: a retrospective database analysis.

  Cardiovascular diabetology 20090101

• Safety and efficacy of rosiglitazone in the elderly diabetic patient.

  Vascular health and risk management 20090101

• Role of PPARα in the control of torpor through FGF21-NPY pathway: From circadian clock to seasonal change in mammals.

  PPAR research 20090101

• [Fibrate-induced deterioration of renal function].

  Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20090101

• Effects of cardiovascular lifestyle change on lipoprotein subclass profiles defined by nuclear magnetic resonance spectroscopy.

  Lipids in health and disease 20090101

• A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease.

  Cardiovascular diabetology 20090101

• Regulation of bile acid and cholesterol metabolism by PPARs.

  PPAR research 20090101

• New options in the treatment of lipid disorders in HIV-infected patients.

  The open AIDS journal 20090101

• Differential transcriptional modulation of duplicated fatty acid-binding protein genes by dietary fatty acids in zebrafish (Danio rerio): evidence for subfunctionalization or neofunctionalization of duplicated genes.

  BMC evolutionary biology 20090101

• Serum uric acid for risk stratification of patients with coronary artery disease.

  Cardiology 20090101

• Susceptibility of pancreatic beta cells to fatty acids is regulated by LXR/PPARalpha-dependent stearoyl-coenzyme A desaturase.

  PloS one 20090101

• Drugs associated with more suicidal ideations are also associated with more suicide attempts.

  PloS one 20090101

• Thinking beyond low-density lipoprotein cholesterol: strategies to further reduce cardiovascular risk.

  Vascular health and risk management 20090101

• Omega-3 polyunsaturated fatty acids: a necessity for a comprehensive secondary prevention strategy.

  Vascular health and risk management 20090101

• Current understanding of the role of PPARγ in gastrointestinal cancers.

  PPAR research 20090101

• Plasmapheresis in a patient with rhabdomyolysis: a case report.

  Cases journal 20090101

• Ciprofibrate increases cholesteryl ester transfer protein gene expression and the indirect reverse cholesterol transport to the liver.

  Lipids in health and disease 20090101

• Membrane omega-3 Fatty Acid deficiency as a preventable risk factor for comorbid coronary heart disease in major depressive disorder.

  Cardiovascular psychiatry and neurology 20090101

• Prediction of pharmacological and xenobiotic responses to drugs based on time course gene expression profiles.

  PloS one 20090101

• Total cholesterol and triglycerides are associated with the development of new bone marrow lesions in asymptomatic middle-aged women - a prospective cohort study.

  Arthritis research & therapy 20090101

• Management of dyslipidemia in children.

  Diabetology & metabolic syndrome 20090101

• Combined bezafibrate and medroxyprogesterone acetate: potential novel therapy for acute myeloid leukaemia.

  PloS one 20090101

• Lack of functional and expression homology between human and mouse aldo-keto reductase 1C enzymes: implications for modelling human cancers.

  Molecular cancer 20090101

• The potential for xanthine oxidase inhibition in the prevention and treatment of cardiovascular and cerebrovascular disease.

  Cardiovascular psychiatry and neurology 20090101

• PPAR/RXR Regulation of Fatty Acid Metabolism and Fatty Acid omega-Hydroxylase (CYP4) Isozymes: Implications for Prevention of Lipotoxicity in Fatty Liver Disease.

  PPAR research 20090101

• Determination of pharmaceuticals in drinking water by CD-modified MEKC: separation optimization using experimental design.

  Journal of separation science 20081201

• Potential relationship between hepatobiliary osteopontin and peroxisome proliferator-activated receptor alpha expression following ethanol-associated hepatic injury in vivo and in vitro.

  Toxicological sciences : an official journal of the Society of Toxicology 20081101

• American College of Endocrinology Pre-Diabetes Consensus Conference: part two.

  Diabetes care 20081101

• Lemon Polyphenols Suppress Diet-induced Obesity by Up-Regulation of mRNA Levels of the Enzymes Involved in beta-Oxidation in Mouse White Adipose Tissue.

  Journal of clinical biochemistry and nutrition 20081101

• Circadian expression of FGF21 is induced by PPARalpha activation in the mouse liver.

  FEBS letters 20081029

• Microwave-assisted micellar extraction coupled with solid-phase extraction for preconcentration of pharmaceuticals in molluscs prior to determination by HPLC.

  Biomedical chromatography : BMC 20081001

• Bezafibrate prevents hepatic stellate cell activation and fibrogenesis in a murine steatohepatitis model, and suppresses fibrogenic response induced by transforming growth factor-beta1 in a cultured stellate cell line.

  Hepatology research : the official journal of the Japan Society of Hepatology 20081001

• Correlation between plasma levels of 7alpha-hydroxy-4-cholesten-3-one and cholesterol 7alpha-hydroxylation rates in vivo in hyperlipidemic patients.

  Steroids 20081001

• Changes in triglyceride levels over time and risk of type 2 diabetes in young men.

  Diabetes care 20081001

• Bezafibrate, a peroxisome proliferator-activated receptors agonist, decreases body temperature and enhances electroencephalogram delta-oscillation during sleep in mice.

  Endocrinology 20081001

• Mice, mitochondria and myopathy.

  Lab animal 20081001

• The peroxisome proliferator activator receptor alpha/delta agonists linoleic acid and bezafibrate upregulate osteoblast differentiation and induce periosteal bone formation in vivo.

  Calcified tissue international 20081001

• Biodegradation of acidic pharmaceuticals in bed sediments: insight from a laboratory experiment.

  Environmental science & technology 20081001

• Sex hormone influence on hepatitis in young male A/JCr mice infected with Helicobacter hepaticus.

  Infection and immunity 20080901

• Aldosterone induces interleukin-18 through endothelin-1, angiotensin II, Rho/Rho-kinase, and PPARs in cardiomyocytes.

  American journal of physiology. Heart and circulatory physiology 20080901

• Activation of the PPAR/PGC-1alpha pathway prevents a bioenergetic deficit and effectively improves a mitochondrial myopathy phenotype.

  Cell metabolism 20080901

• Emerging hematological targets and therapy for cardiovascular disease: From bench to bedside.

  Biologics : targets & therapy 20080901

• The effects of pharmaceuticals on the regeneration of the cnidarian, Hydra attenuata.

  The Science of the total environment 20080825

• Effects of fibrates, anti-inflammatory drugs and antidepressants in the fish hepatoma cell line PLHC-1: cytotoxicity and interactions with cytochrome P450 1A.

  Toxicology in vitro : an international journal published in association with BIBRA 20080801

• Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies.

  Diabetes care 20080801

• Hemodynamic effects of fenofibrate and coenzyme Q10 in type 2 diabetic subjects with left ventricular diastolic dysfunction.

  Diabetes care 20080801

• Effects of statins on high-density lipoproteins: a potential contribution to cardiovascular benefit.

  Cardiovascular drugs and therapy 20080801

• Relation between drug-induced taste disorder and chelating behavior with zinc ion; statistical approach to the drug-induced taste disorder, part II.

  Chemical & pharmaceutical bulletin 20080801

• Comparison of analytical and theoretical pharmaceutical concentrations in human urine in Germany.

  Water research 20080801

• Mendelian randomisation and causal inference in observational epidemiology.

  PLoS medicine 20080801

• The Relationship Between HIV Infection and Cardiovascular Disease.

  Current cardiology reviews 20080801

• Characterization of the drug binding specificity of rat liver fatty acid binding protein.

  Journal of medicinal chemistry 20080710

• Beta-blockers for coronary heart disease in chronic kidney disease.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20080701

• Cholesterol-lowering effect of bezafibrate is independent of peroxisome proliferator-activated receptor activation in mice.

  Biochemical pharmacology 20080701

• Renal L-type fatty acid-binding protein mediates the bezafibrate reduction of cisplatin-induced acute kidney injury.

  Kidney international 20080601

• The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: A prospective, multicenter study.

  Hepatology research : the official journal of the Japan Society of Hepatology 20080601

• Atorvastatin monotherapy vs. combination therapy in the management of patients with combined hyperlipidemia.

  European journal of internal medicine 20080501

• Fluvastatin improves arterial stiffness in patients with coronary artery disease and hyperlipidemia: a 5-year follow-up study.

  Circulation journal : official journal of the Japanese Circulation Society 20080501

• Pharmaceutical residues in the river Rhine--results of a one-decade monitoring programme.

  Journal of environmental monitoring : JEM 20080501

• Cholesterol reduction and atherosclerosis inhibition by bezafibrate in low-density lipoprotein receptor knockout mice.

  Hypertension research : official journal of the Japanese Society of Hypertension 20080501

• Concentrations and mobility of human pharmaceuticals in the world's largest wastewater irrigation system, Mexico City-Mezquital Valley.

  Water research 20080401

• Activation of peroxisome proliferator-activated receptor pathway stimulates the mitochondrial respiratory chain and can correct deficiencies in patients' cells lacking its components.

  The Journal of clinical endocrinology and metabolism 20080401

• The peroxisome: still a mysterious organelle.

  Histochemistry and cell biology 20080401

• Inhibition of advanced glycation end products: an implicit goal in clinical medicine for the treatment of diabetic nephropathy?

  Annals of the New York Academy of Sciences 20080401

• Orlistat in the prevention of diabetes in the obese patient.

  Vascular health and risk management 20080401

• Silent cerebral infarction in chronic heart failure: ischemic and nonischemic dilated cardiomyopathy.

  Vascular health and risk management 20080401

• Discovery of a novel class of 1,3-dioxane-2-carboxylic acid derivatives as subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists.

  Bioorganic & medicinal chemistry letters 20080315

• Identification of photocatalytic degradation products of bezafibrate in TiO(2) aqueous suspensions by liquid and gas chromatography.

  Journal of chromatography. A 20080307

• PPARalpha is involved in photoentrainment of the circadian clock.

  Neuroreport 20080305

• Effects of amlodipine, captopril, and bezafibrate on oxidative milieu in rats with fatty liver.

  Digestive diseases and sciences 20080301

• Effects and interactions in an environmentally relevant mixture of pharmaceuticals.

  Toxicological sciences : an official journal of the Society of Toxicology 20080301

• Poor functional status based on the New York Heart Association classification exposes the coronary patient to an elevated risk of ischemic stroke.

  American heart journal 20080301

• Effects of fibrate drugs on expression of ABCA1 and HDL biogenesis in hepatocytes.

  Journal of cardiovascular pharmacology 20080301

• Lipid synthesis in macrophages during inflammation in vivo: effect of agonists of peroxisome proliferator activated receptors alpha and gamma and of retinoid X receptors.

  Biochemistry. Biokhimiia 20080301

• Vascular and metabolic effects of treatment of combined hyperlipidemia: focus on statins and fibrates.

  International journal of cardiology 20080227

• Bezafibrate decreases growth stimulatory action of the sphingomyelin signaling pathway in regenerating rat liver.

  Prostaglandins & other lipid mediators 20080201

• Update on the use of fibrates: focus on bezafibrate.

  Vascular health and risk management 20080201

• Prediction of calculated future cardiovascular disease by monocyte count in an asymptomatic population.

  Vascular health and risk management 20080201

• High density lipoprotein cholesterol: an evolving target of therapy in the management of cardiovascular disease.

  Vascular health and risk management 20080201

• Secondary prevention with bezafibrate therapy for the treatment of dyslipidemia: an extended follow-up of the BIP trial.

  Journal of the American College of Cardiology 20080129

• An investigation into the acute and chronic toxicity of eleven pharmaceuticals (and their solvents) found in wastewater effluent on the cnidarian, Hydra attenuata.

  The Science of the total environment 20080125

• Structure-activity studies on 1,3-dioxane-2-carboxylic acid derivatives, a novel class of subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists.

  Bioorganic & medicinal chemistry 20080115

• Effect of bezafibrate therapy on atherosclerotic aortic plaques detected by MRI in dyslipidemic patients with hypertriglyceridemia.

  Atherosclerosis 20080101

• Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome?

  Arteriosclerosis, thrombosis, and vascular biology 20080101

• Protection of pancreatic beta-cells: is it feasible?

  Nutrition, metabolism, and cardiovascular diseases : NMCD 20080101

• Primary biliary cirrhosis.

  Orphanet journal of rare diseases 20080101

• Optimal management of combined dyslipidemia: what have we behind statins monotherapy?

  Advances in cardiology 20080101

• Peroxisome proliferator activated receptors and lipoprotein metabolism.

  PPAR research 20080101

• PPAR Agonists and Cardiovascular Disease in Diabetes.

  PPAR research 20080101

• Should We Use PPAR Agonists to Reduce Cardiovascular Risk?

  PPAR research 20080101

• Are fish oil omega-3 long-chain fatty acids and their derivatives peroxisome proliferator-activated receptor agonists?

  Cardiovascular diabetology 20080101

• PPAR Genomics and Pharmacogenomics: Implications for Cardiovascular Disease.

  PPAR research 20080101

• PPAR Ligands for Cancer Chemoprevention.

  PPAR research 20080101

• The Critical Role of PPARgamma in Human Malignant Melanoma.

  PPAR research 20080101

• Multiple Interactions between Peroxisome Proliferators-Activated Receptors and the Ubiquitin-Proteasome System and Implications for Cancer Pathogenesis.

  PPAR research 20080101

• Does the lipid-lowering peroxisome proliferator-activated receptors ligand bezafibrate prevent colon cancer in patients with coronary artery disease?

  Cardiovascular diabetology 20080101

• Peroxisome Proliferators-Activated Receptor (PPAR) Modulators and Metabolic Disorders.

  PPAR research 20080101

• Statin induced myopathy and myalgia: time trend analysis and comparison of risk associated with statin class from 1991-2006.

  PloS one 20080101

• The Role of PPARs in Cancer.

  PPAR research 20080101

• Mitochondria, PPARs, and Cancer: Is Receptor-Independent Action of PPAR Agonists a Key?

  PPAR research 20080101

• Role of peroxisome proliferator-activated receptor alpha in the control of cyclooxygenase 2 and vascular endothelial growth factor: involvement in tumor growth.

  PPAR research 20080101

• PPAR Regulation of Inflammatory Signaling in CNS Diseases.

  PPAR research 20080101

• PPARalpha Ligands as Antitumorigenic and Antiangiogenic Agents.

  PPAR research 20080101

• Peroxisome proliferator-activated receptors in the modulation of the immune/inflammatory response in atherosclerosis.

  PPAR research 20080101

• Statins but not fibrates improve the atherogenic to anti-atherogenic lipoprotein particle ratio: a randomized crossover study.

  BMC clinical pharmacology 20080101

• Effect of dietary n-6/n-3 ratio on liver n-6/n-3 ratio and peroxisomal beta-oxidation activity in rats.

  Journal of oleo science 20080101

• HPLC method for the determination of bezafibrate in human plasma and application to a pharmacokinetic study of bezafibrate dispersible tablet.

  Journal of chromatographic science 20080101

• The Role of PPARs in the Endothelium: Implications for Cancer Therapy.

  PPAR research 20080101

• Predicted mouse peroxisome-targeted proteins and their actual subcellular locations.

  BMC bioinformatics 20080101

• PPARs Mediate Lipid Signaling in Inflammation and Cancer.

  PPAR research 20080101

• Development and Validation of RP-HPLC Method for Simultaneous Estimation of Atorvastatin Calcium and Fenofibrate in Tablet Dosage Forms.

  Indian journal of pharmaceutical sciences 20080101

• 2-Methyl-2-(4-nitro-phenyl-sulfanyl)-propanoic acid.

  Acta crystallographica. Section E, Structure reports online 20080101

• Therapeutic Potential of PPARγ Activation in Stroke.

  PPAR research 20080101

• Multichannel liquid chromatography-tandem mass spectrometry cocktail method for comprehensive substrate characterization of multidrug resistance-associated protein 4 transporter.

  Pharmaceutical research 20071201

• Genetic basis for correction of very-long-chain acyl-coenzyme A dehydrogenase deficiency by bezafibrate in patient fibroblasts: toward a genotype-based therapy.

  American journal of human genetics 20071201

• C-reactive protein, bezafibrate, and recurrent coronary events in patients with chronic coronary heart disease.

  American heart journal 20071201

• Prediction of the metabolic interaction of nateglinide with other drugs based on in vitro studies.

  Drug metabolism and pharmacokinetics 20071201

• Efficacy of pioglitazone in familial partial lipodystrophy of the Dunnigan type: a case report.

  Diabetes & metabolism 20071101

• Agonists of PPAR-alpha, PPAR-gamma, and RXR inhibit the formation of foam cells from macrophages in mice with inflammation.

  Bulletin of experimental biology and medicine 20071101

• Effect of rosuvastatin 5-20mg on triglycerides and other lipid parameters in Japanese patients with hypertriglyceridemia.

  Atherosclerosis 20071001

• Risk of congenital anomalies in pregnant users of statin drugs.

  British journal of clinical pharmacology 20071001

• Effects of blood lipid lowering pharmaceuticals (bezafibrate and gemfibrozil) on immune and digestive gland functions of the bivalve mollusc, Mytilus galloprovincialis.

  Chemosphere 20071001

• Delayed bezafibrate-induced angio-oedema in a 68-year-old man.

  British journal of clinical pharmacology 20071001

• Gene expression profiling of rat liver reveals a mechanistic basis for ritonavir-induced hyperlipidemia.

  Genomics 20071001

• Carboxylic acid drug-induced DNA nicking in HEK293 cells expressing human UDP-glucuronosyltransferases: role of acyl glucuronide metabolites and glycation pathways.

  Chemical research in toxicology 20071001

• Fibrate for treatment of primary biliary cirrhosis.

  Hepatology research : the official journal of the Japan Society of Hepatology 20071001

• [New approaches for the treatment of metabolic myopathies].

  Revue neurologique 20071001

• Long-term effect of bezafibrate on pancreatic beta-cell function and insulin resistance in patients with diabetes.

  Atherosclerosis 20070901

• The clinical relevance of LDL size and subclasses modulation in patients with type-2 diabetes.

  Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 20070901

• Rat liver peroxisomes after fibrate treatment. A survey using quantitative mass spectrometry.

  The Journal of biological chemistry 20070810

• Increase in circulating levels of adiponectin after treatment with statin and fibrate in patients with coronary artery disease and hyperlipidemia.

  Atherosclerosis 20070801

• Influence of HDL-cholesterol-elevating drugs on the in vitro activity of the HDL receptor SR-BI.

  Journal of lipid research 20070801

• Wastewater treatment plants as a pathway for aquatic contamination by pharmaceuticals in the ebro river basin (northeast Spain).

  Environmental toxicology and chemistry 20070801

• [Intervention for hypertriglyceridemia].

  Nihon rinsho. Japanese journal of clinical medicine 20070728

• Mitochondria, ciglitazone and liver: a neglected interaction in biochemical pharmacology.

  European journal of pharmacology 20070712

• Toxic and genotoxic impact of fibrates and their photoproducts on non-target organisms.

  Environment international 20070701

• Bezafibrate induces multidrug-resistance P-Glycoprotein 3 expression in cultured human hepatocytes and humanized livers of chimeric mice.

  Hepatology research : the official journal of the Japan Society of Hepatology 20070701

• Relationship between insulin resistance and low urinary pH in patients with gout, and effects of PPARalpha agonists on urine pH.

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20070701

• Screening method for ecotoxicological hazard assessment of 42 pharmaceuticals considering human metabolism and excretory routes.

  Environmental science & technology 20070615

• PPARalpha is a potential therapeutic target of drugs to treat circadian rhythm sleep disorders.

  Biochemical and biophysical research communications 20070608

• PPARalpha agonists suppress osteopontin expression in macrophages and decrease plasma levels in patients with type 2 diabetes.

  Diabetes 20070601

• Bezafibrate removal by means of ozonation: primary intermediates, kinetics, and toxicity assessment.

  Water research 20070601

• Effect of peroxisome proliferator-activated receptor-alpha agonist (bezafibrate) on gastric secretion and gastric cytoprotection in rats.

  Fundamental & clinical pharmacology 20070601

• Investigating the mechanistic basis for hepatic toxicity induced by an experimental chemokine receptor 5 (CCR5) antagonist using a compendium of gene expression profiles.

  Toxicologic pathology 20070601

• Peroxisome proliferator-activated receptor-gamma agonists inhibit respiratory syncytial virus-induced expression of intercellular adhesion molecule-1 in human lung epithelial cells.

  Immunology 20070501

• The clinical significance of the size of low-density-lipoproteins and the modulation of subclasses by fibrates.

  Current medical research and opinion 20070501

• Cholesterol reduction yields clinical benefits: meta-analysis including recent trials.

  Clinical therapeutics 20070501

• Bezafibrate regulates the expression and enzyme activity of 11beta-hydroxysteroid dehydrogenase type 1 in murine adipose tissue and 3T3-L1 adipocytes.

  American journal of physiology. Endocrinology and metabolism 20070401

• Bezafibrate improves bacterial lipopolysaccharide-induced dyslipidemia and anorexia in rats.

  Metabolism: clinical and experimental 20070401

• The increase in hepatic uncoupling by fenofibrate contributes to a decrease in adipose tissue in obese rats.

  Journal of Korean medical science 20070401

• PPARdelta, but not PPARalpha, activates PGC-1alpha gene transcription in muscle.

  Biochemical and biophysical research communications 20070323

• Binding modes of L35 to alpha- and beta-semihemoglobins: structural insights into the inequivalence of alpha- and beta-subunits of hemoglobin.

  Biochemical and biophysical research communications 20070316

• Lipid-lowering drugs in the MPTP mouse model of Parkinson's disease: fenofibrate has a neuroprotective effect, whereas bezafibrate and HMG-CoA reductase inhibitors do not.

  Brain research 20070302

• Effects of peroxisome proliferator-activated receptor ligands, bezafibrate and fenofibrate, on adiponectin level.

  Arteriosclerosis, thrombosis, and vascular biology 20070301

• PPARalpha siRNA-treated expression profiles uncover the causal sufficiency network for compound-induced liver hypertrophy.

  PLoS computational biology 20070301

• [Establishment of a cell-based high-throughput screening model for PPARdelta agonists].

  Sheng wu gong cheng xue bao = Chinese journal of biotechnology 20070301

• Novel peroxisomal protease Tysnd1 processes PTS1- and PTS2-containing enzymes involved in beta-oxidation of fatty acids.

  The EMBO journal 20070207

• Analysis of pharmaceuticals in wastewater and removal using a membrane bioreactor.

  Analytical and bioanalytical chemistry 20070201

• Silicone rod extraction of pharmaceuticals from water.

  Analytical and bioanalytical chemistry 20070201

• PET/CT quantitation of the effect of patient-related factors on cardiac 18F-FDG uptake.

  Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20070201

• Pharmaceutical determination in surface and wastewaters using high-performance liquid chromatography-(electrospray)-mass spectrometry.

  Journal of separation science 20070201

• Effect of lipid-lowering and anti-hypertensive drugs on plasma homocysteine levels.

  Vascular health and risk management 20070201

• Protective effect of bezafibrate on streptozotocin-induced oxidative stress and toxicity in rats.

  Toxicology 20070105

• Serum homocysteine and long-term risk of myocardial infarction and sudden death in patients with coronary heart disease.

  Cardiology 20070101

• PPAR agonists modulate human osteoclast formation and activity in vitro.

  Bone 20070101

• C-reactive protein distribution and correlates among men and women with chronic coronary heart disease.

  Cardiology 20070101

• PPARs in the Control of Uncoupling Proteins Gene Expression.

  PPAR research 20070101

• PPARs, Obesity, and Inflammation.

  PPAR research 20070101

• Cerebral sinus occlusion in a boy presenting with asparaginase-induced hypertriglyceridemia.

  Klinische Padiatrie 20070101

• Relationships between free radical levels during carotid endarterectomy and markers of arteriosclerotic disease.

  International journal of medical sciences 20070101

• Atypical presentation of a middle age male with severe hypertriglyceridaemia: a case report.

  Journal of medical case reports 20070101

• Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes.

  Cardiovascular diabetology 20070101

• Peroxisome proliferators-activated alpha agonist treatment ameliorates hepatic damage in rats with obstructive jaundice: an experimental study.

  BMC gastroenterology 20070101

• Occurrence of 70 pharmaceutical and personal care products in Tone River basin in Japan.

  Water science and technology : a journal of the International Association on Water Pollution Research 20070101

• Cannabinoids: a new group of agonists of PPARs.

  PPAR research 20070101

• Comprehensive analysis of PPARalpha-dependent regulation of hepatic lipid metabolism by expression profiling.

  PPAR research 20070101

• The direct antioxidative and anti-inflammatory effects of peroxisome proliferator-activated receptors ligands are associated with the inhibition of angiotensin converting enzyme expression in streptozotocin-induced diabetic rat aorta.

  European journal of pharmacology 20061107

• Multitherapy for diabetes.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20061107

• Statins, fibrates, and melanoma risk: a systematic review and meta-analysis.

  Journal of the National Cancer Institute 20061101

• Severe decrease in serum HDL-cholesterol during combination therapy of bezafibrate and pioglitazone.

  Journal of atherosclerosis and thrombosis 20061001

• Allosteric effectors influence the tetramer stability of both R- and T-states of hemoglobin A.

  The Journal of biological chemistry 20060908

• Perchloric acid-soluble protein is expressed in enterocytes and goblet cells in the intestine and upregulated by dietary lipid.

  Biochimica et biophysica acta 20060901

• Keishibukuryogan (gui-zhi-fu-ling-wan), a Kampo formula, decreases disease activity and soluble vascular adhesion molecule-1 in patients with rheumatoid arthritis.

  Evidence-based complementary and alternative medicine : eCAM 20060901

• Key issues in the role of peroxisome proliferator-activated receptor agonism and cell signaling in trichloroethylene toxicity.

  Environmental health perspectives 20060901

• Seasonality effects on pharmaceuticals and s-triazine herbicides in wastewater effluent and surface water from the Canadian side of the upper Detroit River.

  Environmental toxicology and chemistry 20060901

• The interference of pharmaceuticals with endogenous and xenobiotic metabolizing enzymes in carp liver: an in-vitro study.

  Environmental science & technology 20060815

• Effects of bezafibrate on the expression of endothelial nitric oxide synthase gene and its mechanisms in cultured bovine endothelial cells.

  Atherosclerosis 20060801

• Agonists of the peroxisome proliferator-activated receptor alpha induce a fiber-type-selective transcriptional response in rat skeletal muscle.

  Toxicological sciences : an official journal of the Society of Toxicology 20060801

• Decrease in triglyceride level by bezafibrate is related to reduction of recurrent coronary events: a Bezafibrate Infarction Prevention substudy.

  Coronary artery disease 20060801

• Occurrence of pharmaceutical products in a municipal effluent and toxicity to rainbow trout (Oncorhynchus mykiss) hepatocytes.

  Ecotoxicology and environmental safety 20060701

• C-reactive protein as a predictor of incident ischemic stroke among patients with preexisting cardiovascular disease.

  Stroke 20060701

• Effects of bezafibrate in patients with chronic hepatitis C virus infection: combination with interferon and ribavirin.

  Journal of viral hepatitis 20060701

• Bezafibrate may attenuate biliary damage associated with chronic liver diseases accompanied by high serum biliary enzyme levels.

  Journal of gastroenterology 20060701

• CYP4A11 is repressed by retinoic acid in human liver cells.

  FEBS letters 20060612

• Effects of selected pharmaceutical products on phagocytic activity in Elliptio complanata mussels.

  Comparative biochemistry and physiology. Toxicology & pharmacology : CBP 20060601

• Saying 'Yes' to obese living liver donors: short-term intensive treatment for donors with hepatic steatosis in living-donor liver transplantation.

  Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 20060601

• [Bezafibrate alone is an effective first-line therapy for primary sclerosing cholangitis: a case report].

  Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 20060601

• [Bezafibrate up-regulate endothelial nitric oxide gene expressions via peroxisome proliferator-activated receptors alpha-dependent and independent pathways in cultured Bovine endothelial cells].

  Zhonghua xin xue guan bing za zhi 20060601

• Effects of bezafibrate on HDL2/HDL3 ratio in postmenopausal hypertriglyceridemic women.

  Journal of cardiovascular pharmacology and therapeutics 20060601

• Dyslipidaemia in diabetes.

  Clinical evidence 20060601

• Prevention of cardiovascular events in diabetes.

  Clinical evidence 20060601

• Metabolic syndrome, inflammation and atherosclerosis.

  Vascular health and risk management 20060601

• Bezafibrate for the treatment of hypertriglyceridemia in HIV1-infected patients on highly active antiretroviral therapy.

  The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 20060601

• Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review.

  International journal of nanomedicine 20060601

• Separation of fibrate-type antihyperlipidemic drugs by capillary electrophoresis and their quantitation in pharmaceuticals.

  Journal of pharmaceutical and biomedical analysis 20060503

• Tamoxifen induced-non-alcoholic steatohepatitis (NASH): has the time come for the oncologist to be diabetologist.

  Breast cancer research and treatment 20060501

• Microsphere-based protease assays and screening application for lethal factor and factor Xa.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501

• Bioactivation of carboxylic acid compounds by UDP-Glucuronosyltransferases to DNA-damaging intermediates: role of glycoxidation and oxidative stress in genotoxicity.

  Chemical research in toxicology 20060501

• Long-term effect of bezafibrate on parameters of hepatic fibrosis in primary biliary cirrhosis.

  Journal of gastroenterology 20060501

• Differential effects of pyrazinamide and clofibrate on gene expression of rat hepatic alpha-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase, a key enzyme of the tryptophan-NAD pathway.

  International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition 20060501

• Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet.

  European journal of pharmacology 20060424

• Automated on-line renewable solid-phase extraction-liquid chromatography exploiting multisyringe flow injection-bead injection lab-on-valve analysis.

  Analytical chemistry 20060415

• Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate.

  Archives of internal medicine 20060410

• Elevated levels of remnant lipoproteins are associated with plasma platelet microparticles in patients with type-2 diabetes mellitus without obstructive coronary artery disease.

  European heart journal 20060401

• Fish oil increases bile acid synthesis in male patients with hypertriglyceridemia.

  The Journal of nutrition 20060401

• Concomitant suppression of hyperlipidemia and intestinal polyp formation by increasing lipoprotein lipase activity in Apc-deficient mice.

  Biological chemistry 20060401

• Effects of a complex mixture of therapeutic drugs at environmental levels on human embryonic cells.

  Environmental science & technology 20060401

• Bezafibrate reduces the incidence of type 2 diabetes mellitus in patients with obesity.

  Nature clinical practice. Endocrinology & metabolism 20060401

• Fenofibrate activates AMPK and increases eNOS phosphorylation in HUVEC.

  Biochemical and biophysical research communications 20060324

• Non-parametric linear regression of discrete Fourier transform convoluted densitometric peak responses.

  Journal of pharmaceutical and biomedical analysis 20060318

• Development of a toxicogenomics in vitro assay for the efficient characterization of compounds.

  Pharmacogenomics 20060301

• R-state haemoglobin with low oxygen affinity: crystal structures of deoxy human and carbonmonoxy horse haemoglobin bound to the effector molecule L35.

  Journal of molecular biology 20060224

• Relation between on-treatment increments in serum high-density lipoprotein cholesterol levels and cardiac mortality in patients with coronary heart disease (from the Bezafibrate Infarction Prevention trial).

  The American journal of cardiology 20060215

• 'Anti-inflammatory' drugs and their effects on type 2 diabetes.

  Diabetes technology & therapeutics 20060201

• Removal of pharmaceuticals in drinking water treatment: effect of chemical coagulation.

  Environmental technology 20060201

• Candidate gene polymorphism in cardiovascular disease: the BIP cohort.

  The Israel Medical Association journal : IMAJ 20060201

• Adiponectin and the development of diabetes in patients with coronary artery disease and impaired fasting glucose.

  European journal of endocrinology 20060101

• Removal of pharmaceuticals in sewage treatment plants in Italy.

  Environmental science & technology 20060101

• Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism.

  Drugs of today (Barcelona, Spain : 1998) 20060101

• Regulatory effects of synthetic liver X receptor- and peroxisome-proliferator activated receptor agonists on sterol transport pathways in polarized cerebrovascular endothelial cells.

  The international journal of biochemistry & cell biology 20060101

• Chlamydia pneumoniae, heat shock proteins 60 and risk of secondary cardiovascular events in patients with coronary heart disease under special consideration of diabetes: a prospective study.

  BMC cardiovascular disorders 20060101

• Ethanolamine modulates DNA synthesis through epidermal growth factor receptor in rat primary hepatocytes.

  In vitro cellular & developmental biology. Animal 20060101

• Potential of fibrates in the treatment of fatty acid oxidation disorders: revival of classical drugs?

  Journal of inherited metabolic disease 20060101

• Bezafibrate induces FALDH in human fibroblasts; implications for Sjögren-Larsson syndrome.

  Molecular genetics and metabolism 20060101

• Evaluation of tumour necrosis factor alpha, interleukin-2 soluble receptor, nitric oxide metabolites, and lipids as inflammatory markers in type 2 diabetes mellitus.

  Mediators of inflammation 20060101

• Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins.

  Cardiovascular diabetology 20060101

• Differential gene expression in mouse primary hepatocytes exposed to the peroxisome proliferator-activated receptor alpha agonists.

  BMC bioinformatics 20060101

• Examination of Ligand-Dependent Coactivator Recruitment by Peroxisome Proliferator-Activated Receptor-alpha (PPARalpha).

  PPAR research 20060101

• K-111: the emerging evidence for its potential in the treatment of the metabolic syndrome.

  Core evidence 20060101

• PPARalpha activation upregulates nephrin expression in human embryonic kidney epithelial cells and podocytes by a dual mechanism.

  Biochemical and biophysical research communications 20051230

• Fibrate prevents cisplatin-induced proximal tubule cell death.

  Kidney international 20051201

• Genetic variation in the hepatic lipase gene is associated with combined hyperlipidemia, plasma lipid concentrations, and lipid-lowering drug response.

  American heart journal 20051201

• Optimal lipid modification: the rationale for combination therapy.

  Vascular health and risk management 20051201

• Fibrates inhibit aldose reductase activity in the forward and reverse reactions.

  Biochemical pharmacology 20051125

• The other side of the bezafibrate infarction prevention trial data.

  Archives of internal medicine 20051114

• NAD(P)H oxidase/nitric oxide interactions in peroxisome proliferator activated receptor (PPAR)alpha-mediated cardiovascular effects.

  Mutation research 20051111

• Statins and PPARalpha agonists induce myotoxicity in differentiated rat skeletal muscle cultures but do not exhibit synergy with co-treatment.

  Toxicology and applied pharmacology 20051101

• Removal of selected pharmaceuticals, fragrances and endocrine disrupting compounds in a membrane bioreactor and conventional wastewater treatment plants.

  Water research 20051101

• Hypertriglyceridemia-why, when and how should it be treated?

  Zeitschrift fur Kardiologie 20051101

• Differential associations of statin and fibrate treatment with carotid arterial remodeling.

  American journal of hypertension 20051101

• Seasonal variation in the occurrence of pharmaceuticals in effluents from a sewage treatment plant and in the recipient water.

  Environmental science & technology 20051101

• Severe hypercholesterolemia associated with decreased hepatic triglyceride lipase activity and pseudohyponatremia in patients after allogeneic stem cell transplantation.

  International journal of hematology 20051101

• Comparing pharmaceutical and pesticide loads into a small Mediterranean river.

  The Science of the total environment 20051015

• The forgotten majority: unfinished business in cardiovascular risk reduction.

  Journal of the American College of Cardiology 20051004

• Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients.

  European heart journal 20051001

• Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin.

  Basic & clinical pharmacology & toxicology 20051001

• Rapid-onset primary biliary cirrhosis resembling drug-induced liver injury.

  Internal medicine (Tokyo, Japan) 20051001

• [Drug combinations: statins and fibrates].

  Arquivos brasileiros de cardiologia 20051001

• [Hypolipidemic therapy under special conditions: acquired immune deficiency syndrome].

  Arquivos brasileiros de cardiologia 20051001

• Bezafibrate increases very-long-chain acyl-CoA dehydrogenase protein and mRNA expression in deficient fibroblasts and is a potential therapy for fatty acid oxidation disorders.

  Human molecular genetics 20050915

• Short-term intensive treatment for donors with hepatic steatosis in living-donor liver transplantation.

  Transplantation 20050915

• Chronic hyperglycemia, independent of plasma lipid levels, is sufficient for the loss of beta-cell differentiation and secretory function in the db/db mouse model of diabetes.

  Diabetes 20050901

• A teleost in vitro reporter gene assay to screen for agonists of the peroxisome proliferator-activated receptors.

  Environmental toxicology and chemistry 20050901

• [A case report of acute neuromyopathy induced by concomitant use of colchicine and bezafibrate].

  No to shinkei = Brain and nerve 20050901

• Vascular endothelium as a target of beraprost sodium and fenofibrate for antiatherosclerotic therapy in type 2 diabetes mellitus.

  Vascular health and risk management 20050901

• Quaternary structures of intermediately ligated human hemoglobin a and influences from strong allosteric effectors: resonance Raman investigation.

  Biophysical journal 20050801

• Remnant lipoproteinemia is a risk factor for endothelial vasomotor dysfunction and coronary artery disease in metabolic syndrome.

  Atherosclerosis 20050801

• Identification of the pharmaceuticals for human use contaminating the Italian aquatic environment.

  Journal of hazardous materials 20050715

• Regulated expression of endothelial lipase by porcine brain capillary endothelial cells constituting the blood-brain barrier.

  Journal of neurochemistry 20050701

• Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia.

  AIDS (London, England) 20050701

• Pigmented purpuric dermatosis (capillaritis) induced by bezafibrate.

  Journal of the American Academy of Dermatology 20050701

• Pathways and metabolites of microbial degradation of selected acidic pharmaceutical and their occurrence in municipal wastewater treated by a membrane bioreactor.

  Water research 20050701

• Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport.

  Xenobiotica; the fate of foreign compounds in biological systems 20050701

• The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid beta-oxidation.

  Oncogene 20050616

• The gene encoding the human ileal bile acid-binding protein (I-BABP) is regulated by peroxisome proliferator-activated receptors.

  Biochimica et biophysica acta 20050615

• Effects of bezafibrate on lipoprotein subclasses and inflammatory markers in patients with hypertriglyceridemia--a nuclear magnetic resonance study.

  International journal of cardiology 20050608

• [Possibilities in the treatment of primary biliary cirrhosis].

  Orvosi hetilap 20050605

• Occurrence of acidic pharmaceuticals in raw and treated sewages and in receiving waters.

  Water research 20050601

• Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome.

  Archives of internal medicine 20050523

• The interaction of lipophilic drugs with intestinal fatty acid-binding protein.

  The Journal of biological chemistry 20050506

• Fructose-induced fatty liver disease: hepatic effects of blood pressure and plasma triglyceride reduction.

  Hypertension (Dallas, Tex. : 1979) 20050501

• Bezafibrate suppresses rat antiglomerular basement membrane crescentic glomerulonephritis.

  Kidney international 20050501

• Triglyceride-lowering effect of respiratory uncoupling in white adipose tissue.

  Obesity research 20050501

• Long-term fibrate treatment for PBC.

  Journal of gastroenterology 20050501

• Statistical approach to drug-induced taste disorders based on zinc chelating ability.

  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20050401

• Synthesis and structure-activity relationship of 4-substituted benzoic acids and their inhibitory effect on the biosynthesis of fatty acids and sterols.

  Archiv der Pharmazie 20050401

• Mizoribine-induced rhabdomyolysis in a rheumatoid arthritis patient receiving bezafibrate treatment.

  The American journal of the medical sciences 20050401

• Effect of anticholesterol therapy on soluble ICAM-1 in chronic stroke patients with hyperlipidemia.

  The Tokai journal of experimental and clinical medicine 20050401

• Operational options to reduce matrix effects in liquid chromatography-electrospray ionization-mass spectrometry analysis of aqueous environmental samples.

  Journal of chromatography. A 20050304

• Peroxisome proliferator activated receptor delta (PPARdelta) agonist but not PPARalpha corrects carnitine palmitoyl transferase 2 deficiency in human muscle cells.

  The Journal of clinical endocrinology and metabolism 20050301

• Liganded hemoglobin structural perturbations by the allosteric effector L35.

  Biophysical journal 20050301

• Treatment of fibrate-induced rhabdomyolysis with plasma exchange in ESRD.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20050301

• Risk reduction therapy for syndrome X: comparison of several treatments.

  American journal of hypertension 20050301

• Fenofibrate induces apoptotic injury in cultured human hepatocytes by inhibiting phosphorylation of Akt.

  Apoptosis : an international journal on programmed cell death 20050301

• Comparison of endothelial function in patients with metabolic syndrome on bezafibrate or atorvastatin therapy.

  Cardiovascular drugs and therapy 20050301

• Expression of cFABP and PPAR in trophoblast cells: effect of PPAR ligands on linoleic acid uptake and differentiation.

  Biochimica et biophysica acta 20050221

• The dual PPARalpha/gamma agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats.

  British journal of pharmacology 20050201

• Therapeutic efficacy of decreased nitrite production by bezafibrate in patients with primary biliary cirrhosis.

  Journal of gastroenterology 20050201

• Role of peroxisome proliferator-activated receptor-alpha (PPARalpha) in bezafibrate-induced hepatocarcinogenesis and cholestasis.

  Carcinogenesis 20050101

• The sialic acid content of fibrinogen decreases during pregnancy and increases in response to fibrate therapy.

  Thrombosis research 20050101

• The 'Statinth' wonder of the world: a panacea for all illnesses or a bubble about to burst.

  Journal of negative results in biomedicine 20050101

• Peroxisome proliferator-activated receptors (PPAR) agonists affect cell viability, apoptosis and expression of cell cycle related proteins in cell lines of glial brain tumors.

  Neoplasma 20050101

• Bezafibrates cause moderate, reversible impairment in renal function in patients without prior renal disease.

  Nephron. Clinical practice 20050101

• Study of the liquid chromatography retention of some fibrate-type antihyperlipidemic drugs on C18 and CN columns: application for quantitation in pharmaceutical formulations.

  Journal of AOAC International 20050101

• Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands.

  BMC cancer 20050101

• Statins research unfinished saga: desirability versus feasibility.

  Cardiovascular diabetology 20050101

• A two-dimensional electrophoresis preliminary approach to human hepatocarcinoma differentiation induced by PPAR-agonists.

  Journal of cellular and molecular medicine 20050101

• Reversal of high dietary fructose-induced PPARalpha suppression by oral administration of lipoxygenase/cyclooxygenase inhibitors.

  Nutrition & metabolism 20050101

• Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481].

  Cardiovascular diabetology 20050101

• A nuclear receptor-mediated choleretic action of fibrates is associated with enhanced canalicular membrane fluidity and transporter activity mediating bile acid-independent bile secretion.

  Journal of atherosclerosis and thrombosis 20050101

• The pathophysiological function of peroxisome proliferator-activated receptor-gamma in lung-related diseases.

  Respiratory research 20050101

• Management of high triglycerides: what non-specialists in lipids need to know.

  Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese 20050101

• Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons.

  Cardiovascular diabetology 20050101

• The antihyperlipidemic activities of 4(3H) quinazolinone and two halogenated derivatives in rats.

  Lipids in health and disease 20050101

• Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20050101

• Association of common variation in the PPARA gene with incident myocardial infarction in individuals with type 2 diabetes: a Go-DARTS study.

  Nuclear receptor 20050101

• Effectiveness of nicotinic acid and bezafibrate alone and in combination for reducing serum triglyceride level.

  Kathmandu University medical journal (KUMJ) 20050101

• Fibrates.

  Handbook of experimental pharmacology 20050101

• Suitability of hollow fibre liquid-phase microextraction for the determination of acidic pharmaceuticals in wastewater by liquid chromatography-electrospray tandem mass spectrometry without matrix effects.

  Journal of chromatography. A 20041217

• Effects of a novel anti-hyperlipidemic agent, S-2E, on blood lipid levels in rats with fructose-induced hypertriglyceridemia.

  Pharmacology 20041201

• Role of energy charge and AMP-activated protein kinase in adipocytes in the control of body fat stores.

  International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity 20041201

• Short-term effect of bezafibrate on the expression of adiponectin mRNA in the adipose tissues: a study in spontaneously type 2 diabetic rats with visceral obesity.

  Endocrine 20041201

• Evidence for a new human CYP1A1 regulation pathway involving PPAR-alpha and 2 PPRE sites.

  Gastroenterology 20041101

• Reduction of serum HCV RNA titer by bezafibrate therapy in patients with chronic hepatitis C.

  The American journal of gastroenterology 20041101

• Multidrug resistance3 is in situ detected in the liver of patients with primary biliary cirrhosis, and induced in human hepatoma cells by bezafibrate.

  Hepatology research : the official journal of the Japan Society of Hepatology 20041101

• Metabolic regulation of leptin production in adipocytes: a role of fatty acid synthesis intermediates.

  The Journal of nutritional biochemistry 20041101

• Fenofibrate impairs rat mitochondrial function by inhibition of respiratory complex I.

  The Journal of pharmacology and experimental therapeutics 20041001

• Bezafibrate stimulates canalicular localization of NBD-labeled PC in HepG2 cells by PPARalpha-mediated redistribution of ABCB4.

  Journal of lipid research 20041001

• Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide.

  British journal of clinical pharmacology 20041001

• Determination of some acidic drugs in surface and sewage treatment plant waters by capillary electrophoresis-electrospray ionization-mass spectrometry.

  Electrophoresis 20041001

• Peroxisome proliferator-activated receptor and farnesoid X receptor ligands differentially regulate sebaceous differentiation in human sebaceous gland organ cultures in vitro.

  The British journal of dermatology 20041001

• Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1.

  PLoS medicine 20041001

• Functional analysis of peroxisome-proliferator-responsive element motifs in genes of fatty acid-binding proteins.

  The Biochemical journal 20040815

• PPARalpha agonists stimulate progastrin production in human colorectal carcinoma cells.

  Regulatory peptides 20040815

• Analysis by liquid chromatography-electrospray ionization tandem mass spectrometry and acute toxicity evaluation for beta-blockers and lipid-regulating agents in wastewater samples.

  Journal of chromatography. A 20040813

• Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes.

  Journal of medicinal chemistry 20040812

• Effects of pravastatin and bezafibrate on biliary lipid excretion and hepatic expression of Abcg5 and Abcg8 in the rat.

  Journal of gastroenterology and hepatology 20040801

• Mitochondrial respiratory chain dysfunction, a non-receptor-mediated effect of synthetic PPAR-ligands: biochemical and pharmacological implications.

  Biochemical and biophysical research communications 20040702

• Dissociation of oxidant production by peroxisome proliferator-activated receptor ligands from cell death in human cell lines.

  Free radical biology & medicine 20040701

• A novel selective peroxisome proliferator-activated receptor alpha agonist, 2-methyl-c-5-[4-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]butyl]-1,3-dioxane-r-2-carboxylic acid (NS-220), potently decreases plasma triglyceride and glucose levels and modifies lipoprotein profiles in KK-Ay mice.

  The Journal of pharmacology and experimental therapeutics 20040601

• Prevention of cardiovascular events in diabetes.

  Clinical evidence 20040601

• Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease.

  Circulation 20040511

• Effect of peroxisome proliferator-activated receptor alpha on human angiotensinogen promoter.

  International journal of molecular medicine 20040501

• Sucrose-induced cardiomyocyte dysfunction is both preventable and reversible with clinically relevant treatments.

  American journal of physiology. Endocrinology and metabolism 20040501

• Decreased circulating Fas ligand in patients with familial combined hyperlipidemia or carotid atherosclerosis: normalization by atorvastatin.

  Journal of the American College of Cardiology 20040407

• Peroxisome proliferator-activated receptor alpha agonists increase nitric oxide synthase expression in vascular endothelial cells.

  Arteriosclerosis, thrombosis, and vascular biology 20040401

• Bezafibrate on lipids and glucose metabolism in obese diabetic Otsuka Long-Evans Tokushima fatty rats.

  Metabolism: clinical and experimental 20040401

• Bezafibrate and simvastatin: different beneficial effects for different therapeutic aims.

  The Journal of clinical endocrinology and metabolism 20040401

• Is hypoglycaemia a marker for increased long-term mortality risk in patients with coronary artery disease? An 8-year follow-up.

  European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology 20040401

• Potential of capillary-column-switching liquid chromatography-tandem mass spectrometry for the quantitative trace analysis of small molecules. Application to the on-line screening of drugs in water.

  Journal of chromatography. A 20040326

• The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy.

  Current atherosclerosis reports 20040301

• Expression and function of peroxisome proliferator-activated receptors in human melanocytes.

  The British journal of dermatology 20040301

• Predictive value of elevated white blood cell count in patients with preexisting coronary heart disease: the Bezafibrate Infarction Prevention Study.

  Archives of internal medicine 20040223

• Liquid chromatography with triple-quadrupole or quadrupole-time of flight mass spectrometry for screening and confirmation of residues of pharmaceuticals in water.

  Analytical and bioanalytical chemistry 20040201

• Fibrates modify the expression of key factors involved in bile-acid synthesis and biliary-lipid secretion in gallstone patients.

  European journal of clinical pharmacology 20040201

• High fasting glucose levels as a predictor of worse clinical outcome in patients with coronary artery disease: results from the Bezafibrate Infarction Prevention (BIP) study.

  American heart journal 20040201

• Effect of bezafibrate on plasma homocysteine concentration in men with lower extremity arterial disease.

  Journal of thrombosis and haemostasis : JTH 20040201

• Influence of lipid lowering fibrates on P-glycoprotein activity in vitro.

  Biochemical pharmacology 20040115

• PPARalpha controls the intracellular coenzyme A concentration via regulation of PANK1alpha gene expression.

  Journal of lipid research 20040101

• Influence of fibrate treatment on malondialdehyde-modified LDL concentration.

  Clinica chimica acta; international journal of clinical chemistry 20040101

• Chlamydia pneumoniae and future risk in patients with coronary heart disease.

  International journal of cardiology 20040101

• Role of fibrates in reducing coronary risk: a UK Consensus.

  Current medical research and opinion 20040101

• Sensitive determination of acidic drugs and triclosan in surface and wastewater by ion-pair reverse-phase liquid chromatography/tandem mass spectrometry.

  Rapid communications in mass spectrometry : RCM 20040101

• Plant sterols: factors affecting their efficacy and safety as functional food ingredients.

  Lipids in health and disease 20040101

• [Fibrates: mechanism of action, effect on levels of lipids and lipoproteins, risk of coronary events. Part 1. Clofibrate, gemfibrosil, besafibrate].

  Kardiologiia 20040101

• Elevated white cell count in acute coronary syndromes: relationship to variants in inflammatory and thrombotic genes.

  BMC medical genetics 20040101

• [Comparative efficiency of prolonged diet and drug therapies for hyperlipidemias in patients with ischemic heart disease].

  Klinicheskaia meditsina 20040101

• Isomorphic response in eruptive xanthomas.

  Dermatology (Basel, Switzerland) 20040101

• Application of UV-derivative spectra for determination of four antihyperlipidaemic drugs in pharmaceutical formulations.

  Acta poloniae pharmaceutica 20040101

• A retinoid X receptor (RXR)-selective retinoid reveals that RXR-alpha is potentially a therapeutic target in breast cancer cell lines, and that it potentiates antiproliferative and apoptotic responses to peroxisome proliferator-activated receptor ligands.

  Breast cancer research : BCR 20040101

• Bezafibrate-induced changes over time in the expression of uncoupling protein (UCP) mRNA in the tissues: a study in spontaneously type 2 diabetic rats with visceral obesity.

  Journal of atherosclerosis and thrombosis 20040101

• Significance of high density lipoprotein-cholesterol in cardiovascular risk prevention: recommendations of the HDL Forum.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20040101

• Comparison of the behaviour of selected micropollutants in a membrane bioreactor and a conventional wastewater treatment plant.

  Water science and technology : a journal of the International Association on Water Pollution Research 20040101

• Carbamazepine, diclofenac, ibuprofen and bezafibrate--investigations on the behaviour of selected pharmaceuticals during wastewater treatment.

  Water science and technology : a journal of the International Association on Water Pollution Research 20040101

• The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. [ISRCTN64783481].

  Cardiovascular diabetology 20040101

• Which is the best lipid-modifying strategy in metabolic syndrome and diabetes: fibrates, statins or both?

  Cardiovascular diabetology 20040101

• Determination of acidic pharmaceuticals, antibiotics and ivermectin in river sediment using liquid chromatography-tandem mass spectrometry.

  Journal of chromatography. A 20031222

• Novel PPARgamma-dependent and independent effects for thiazolidinediones.

  Current opinion in lipidology 20031201

• Occurrence of neutral and acidic drugs in the effluents of Canadian sewage treatment plants.

  Environmental toxicology and chemistry 20031201

• Effects of bezafibrate and simvastatin on endothelial activation and lipid peroxidation in hypercholesterolemia: evidence of different vascular protection by different lipid-lowering treatments.

  The Journal of clinical endocrinology and metabolism 20031101

• Bezafibrate induces a mitochondrial derangement in human cell lines: a PPAR-independent mechanism for a peroxisome proliferator.

  Chemical research in toxicology 20031101

• Current smoking, smoking cessation, and the risk of sudden cardiac death in patients with coronary artery disease.

  Archives of internal medicine 20031027

• Correction of fatty acid oxidation in carnitine palmitoyl transferase 2-deficient cultured skin fibroblasts by bezafibrate.

  Pediatric research 20031001

• Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin + fibrate (bezafibrate, fenofibrate, or gemfibrozil).

  The American journal of cardiology 20031001

• [Systemic lupus erythematosus with steroid induced non-alcoholic steatohepatitis: a case report].

  Ryumachi. [Rheumatism] 20031001

• Concomitant suppression of hyperlipidemia and intestinal polyp formation in Apc-deficient mice by peroxisome proliferator-activated receptor ligands.

  Cancer research 20030915

• Relationship between peroxisome proliferator-activated receptors (PPAR alpha and PPAR gamma) and endothelium-dependent relaxation in streptozotocin-induced diabetic rats.

  British journal of pharmacology 20030901

• Design, synthesis, and evaluation of substituted phenylpropanoic acid derivatives as human peroxisome proliferator activated receptor activators. Discovery of potent and human peroxisome proliferator activated receptor alpha subtype-selective activators.

  Journal of medicinal chemistry 20030814

• LPS-induced neutrophilic inflammation and Bcl-2 expression in metaplastic mucous cells.

  American journal of physiology. Lung cellular and molecular physiology 20030801

• The peroxisome-proliferator-activated receptor alpha agonist ciprofibrate severely aggravates hypercholesterolaemia and accelerates the development of atherosclerosis in mice lacking apolipoprotein E.

  The Biochemical journal 20030801

• Decreased PLTP mass but elevated PLTP activity linked to insulin resistance in HTG: effects of bezafibrate therapy.

  Journal of lipid research 20030801

• Disappearance of intraglomerular lipoprotein thrombi and marked improvement of nephrotic syndrome by bezafibrate treatment in a patient with lipoprotein glomerulopathy.

  Atherosclerosis 20030801

• Fibrates and statins rapidly and synergistically induce pyruvate dehydrogenase kinase 4 mRNA in the liver and muscles of mice.

  Biological & pharmaceutical bulletin 20030701

• Therapeutic implications of recent ATP III guidelines and the important role of combination therapy in total dyslipidemia management.

  Current opinion in cardiology 20030701

• Bezafibrate is a dual ligand for PPARalpha and PPARbeta: studies using null mice.

  Biochimica et biophysica acta 20030610

• Evaluation of the synergistic adverse effects of concomitant therapy with statins and fibrates on rhabdomyolysis.

  The Journal of pharmacy and pharmacology 20030601

• Combination therapy with PPARgamma and PPARalpha agonists increases glucose-stimulated insulin secretion in db/db mice.

  American journal of physiology. Endocrinology and metabolism 20030501

• Differential effects of peroxisome proliferator-activated receptor activators on the mRNA levels of genes involved in lipid metabolism in primary human monocyte-derived macrophages.

  Metabolism: clinical and experimental 20030501

• Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART.

  AIDS (London, England) 20030411

• Bezafibrate, a peroxisome proliferator-activated receptor (PPAR)-alpha activator, prevents pancreatic degeneration in obese and diabetic rats.

  Pancreas 20030401

• Bezafibrate improves hypertension and insulin sensitivity in humans.

  Hypertension research : official journal of the Japanese Society of Hypertension 20030401

• Effects of bezafibrate and pravastatin on remnant-like lipoprotein particles and lipoprotein subclasses in type 2 diabetes.

  Diabetes research and clinical practice 20030301

• PPAR agonists protect mesangial cells from interleukin 1beta-induced intracellular lipid accumulation by activating the ABCA1 cholesterol efflux pathway.

  Journal of the American Society of Nephrology : JASN 20030301

• Prospective study of serum homocysteine and risk of ischemic stroke among patients with preexisting coronary heart disease.

  Stroke 20030301

• Effects of hypolipidemic treatment on serum markers of vascular inflammation in dyslipidemic men.

  Medical science monitor : international medical journal of experimental and clinical research 20030301

• Cell-specific toxicity of fibrates in human embryonal rhabdomyosarcoma cells.

  Naunyn-Schmiedeberg's archives of pharmacology 20030301

• Oxidation of pharmaceuticals during ozonation and advanced oxidation processes.

  Environmental science & technology 20030301

• Functional class in patients with heart failure is associated with the development of diabetes.

  The American journal of medicine 20030301

• A systematic review of the effectiveness of garlic as an anti-hyperlipidemic agent.

  Journal of the American Academy of Nurse Practitioners 20030301

• Suppression of experimental crescentic glomerulonephritis by peroxisome proliferator-activated receptor (PPAR)gamma activators.

  Clinical and experimental nephrology 20030301

• Progressive development of insulin resistance phenotype in male mice with complete aromatase (CYP19) deficiency.

  The Journal of endocrinology 20030201

• Inhibition of TNF-alpha-induced RANTES expression in human hepatocyte-derived cells by fibrates, the hypolipidemic drugs.

  International immunopharmacology 20030201

• Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkappa B-C/EBP-beta complex formation.

  Blood 20030115

• Frequency of creatine kinase elevation during treatment with fluvastatin in combination with fibrates (bezafibrate, fenofibrate, or gemfibrozil).

  The American journal of cardiology 20030115

• Gall bladder dysmotility: a risk factor for gall stone formation in hypertriglyceridaemia and reversal on triglyceride lowering therapy by bezafibrate and fish oil.

  Gut 20030101

• Fenofibrate-induced hyperhomocysteinaemia: clinical implications and management.

  Drug safety 20030101

• Re: Gómez-Gerique, et al. Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia. Atherosclerosis 2002;162:245-51.

  Atherosclerosis 20030101

• Troglitazone reduces activity of the Na+/H+ exchanger in fructose-fed borderline hypertensive rats.

  Hypertension research : official journal of the Japanese Society of Hypertension 20030101

• [Peroxisome proliferator activated receptors and cardiovascular disorders].

  Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology 20030101

• Efficacy of bezafibrate in a patient with primary sclerosing cholangitis.

  Journal of gastroenterology 20030101

• Bezafibrate treatment: a new medical approach for PBC patients?

  Journal of gastroenterology 20030101

• Metabolic syndrome and type 2 diabetes mellitus: focus on peroxisome proliferator activated receptors (PPAR).

  Cardiovascular diabetology 20030101

• New weapon for primary biliary cirrhosis from Japan.

  Journal of gastroenterology 20030101

• Follow-up CT findings of tamoxifen-induced non-alcoholic steatohepatitis (NASH) of breast cancer patients treated with bezafibrate.

  Oncology reports 20030101

• [Lipoproteins HDL and coronary artery disease: a molecular mechanism of fibrate].

  Przeglad lekarski 20030101

• Functional capacity impairment in patients with coronary artery disease: prevalence, risk factors and prognosis.

  Cardiology 20030101

• Paradoxical severe decrease in serum HDL-cholesterol after treatment with a fibrate: reply by the authors.

  Journal of clinical pathology 20021201

• Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) activation suppresses ischemic induction of Egr-1 and its inflammatory gene targets.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20021201

• Bezafibrate-induced improvement in glucose uptake and endothelial function in protease inhibitor-associated insulin resistance.

  Journal of internal medicine 20021201

• Fibrate treatment does not modify the expression of acyl coenzyme A oxidase in human liver.

  Clinical pharmacology and therapeutics 20021201

• Pharmacoeconomic evaluation of anti-hyperlipidemic agent fenofibrate.

  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20021201

• Bezafibrate in men with lower extremity arterial disease: randomised controlled trial.

  BMJ (Clinical research ed.) 20021116

• Effects of various fibrates on serum alkaline phosphatase activity.

  Atherosclerosis 20021101

• AZ 242, a novel PPARalpha/gamma agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats.

  Journal of lipid research 20021101

• Regulation of uncoupling protein-2 mRNA in L6 myotubules: II: Thyroid hormone amplifies stimulation of uncoupling protein-2 gene by thiazolidinediones and other peroxisome proliferator-activated receptor ligands in L6 myotubules: evidence for a priming effect.

  Endocrine 20021101

• Crystal structure of horse carbonmonoxyhemoglobin-bezafibrate complex at 1.55-A resolution. A novel allosteric binding site in R-state hemoglobin.

  The Journal of biological chemistry 20021011

• [Syndrome X].

  Nihon rinsho. Japanese journal of clinical medicine 20021001

• Peroxisome proliferator-activated receptor beta expression in human breast epithelial cell lines of tumorigenic and non-tumorigenic origin.

  The international journal of biochemistry & cell biology 20020901

• Paradoxical severe decrease in serum HDL-cholesterol after treatment with a fibrate.

  Journal of clinical pathology 20020901

• Soluble intercellular adhesion molecule-1 and risk of future ischemic stroke: a nested case-control study from the Bezafibrate Infarction Prevention (BIP) study cohort.

  Stroke 20020901

• Removal of pharmaceuticals during drinking water treatment.

  Environmental science & technology 20020901

• [Guideline for management of lipid metabolism].

  Nihon rinsho. Japanese journal of clinical medicine 20020901

• Fibrates suppress chenodeoxycholic acid-induced RANTES expression through inhibition of NF-kappaB activation.

  European journal of pharmacology 20020712

• Heterotropic effectors control the hemoglobin function by interacting with its T and R states--a new view on the principle of allostery.

  Biophysical chemistry 20020710

• Genetic determinants of the response to bezafibrate treatment in the lower extremity arterial disease event reduction (LEADER) trial.

  Atherosclerosis 20020701

• Inhibition of phosphatidylcholine synthesis via the phosphatidylethanolamine methylation pathway impairs incorporation of bulk lipids into VLDL in cultured rat hepatocytes.

  Journal of lipid research 20020701

• Modulation by nutrients and drugs of liver acyl-CoAs analyzed by mass spectrometry.

  Journal of lipid research 20020701

• Beneficial effect of bezafibrate on primary sclerosing cholangitis (three case reports).

  The American journal of gastroenterology 20020701

• Peroxisome proliferator-activated receptor agonists, hyperlipidaemia, and atherosclerosis.

  Pharmacology & therapeutics 20020701

• Angioscopic evaluation of stabilizing effects of an antilipemic agent, bezafibrate, on coronary plaques in patients with coronary artery disease: a multicenter prospective study.

  Japanese heart journal 20020701

• [Uncoupling protein-3 in skeletal muscle].

  Nihon rinsho. Japanese journal of clinical medicine 20020701

• [Glucose intolerance in liver diseases].

  Nihon rinsho. Japanese journal of clinical medicine 20020701

• Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia.

  Atherosclerosis 20020601

• Enhanced GLUT2 gene expression in an oleic acid-induced in vitro fatty liver model.

  Hepatology research : the official journal of the Japan Society of Hepatology 20020601

• Allelic polymorphism -491A/T in apo E gene modulates the lipid-lowering response in combined hyperlipidemia treatment.

  European journal of clinical investigation 20020601

• Mouse PeP: a novel peroxisomal protein linked to myoblast differentiation and development.

  Developmental dynamics : an official publication of the American Association of Anatomists 20020601

• Low- and high-density lipoprotein cholesterol and ischemic cerebrovascular disease: the bezafibrate infarction prevention registry.

  Archives of internal medicine 20020513

• Does participation in a long-term clinical trial lead to survival gain for patients with coronary artery disease?

  The American journal of medicine 20020501

• [Fibrates].

  Nihon rinsho. Japanese journal of clinical medicine 20020501

• Is immigration associated with an increase in risk factors and mortality among coronary artery disease patients? A cohort study of 13,742 patients.

  The Israel Medical Association journal : IMAJ 20020501

• Tamoxifen-induced nonalcoholic steatohepatitis in breast cancer patients treated with adjuvant tamoxifen.

  Internal medicine (Tokyo, Japan) 20020501

• Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.

  The Journal of biological chemistry 20020419

• Analysis of acidic drugs in the effluents of sewage treatment plants using liquid chromatography-electrospray ionization tandem mass spectrometry.

  Journal of chromatography. A 20020405

• Soluble intercellular adhesion molecule-1 and long-term risk of acute coronary events in patients with chronic coronary heart disease. Data from the Bezafibrate Infarction Prevention (BIP) Study.

  Journal of the American College of Cardiology 20020403

• Marked removal of bezafibrate-induced high-density lipoprotein-cholesterol by low-density lipoprotein apheresis.

  Clinica chimica acta; international journal of clinical chemistry 20020401

• Aromatase-deficient (ArKO) mice are retrieved from severe hepatic steatosis by peroxisome proliferator administration.

  Hepatology research : the official journal of the Japan Society of Hepatology 20020401

• Is bezafibrate histologically effective for primary biliary cirrhosis?

  The American journal of gastroenterology 20020401

• Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial.

  The American journal of medicine 20020301

• Are high-density lipoprotein and triglyceride levels important in secondary prevention: impressions from the BIP and VA-HIT trials.

  International journal of cardiology 20020301

• Evaluation of myopathy risk for HMG-CoA reductase inhibitors by urethane infusion method.

  Biological & pharmaceutical bulletin 20020301

• Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity.

  Journal of medicinal chemistry 20020214

• [A case of primary sclerosing cholangitis presenting transient hypoperfusion and treated with bezafibrate beneficially].

  Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 20020201

• Fibrate and statin synergistically increase the transcriptional activities of PPARalpha/RXRalpha and decrease the transactivation of NFkappaB.

  Biochemical and biophysical research communications 20020111

• Design, synthesis and evaluation of substituted phenylpropanoic acid derivatives as peroxisome proliferator-activated receptor (PPAR) activators: novel human PPARalpha-selective activators.

  Bioorganic & medicinal chemistry letters 20020107

• Prevention of radiation-induced mammary tumors.

  International journal of radiation oncology, biology, physics 20020101

• Severity of angina pectoris and risk of ischemic stroke.

  Stroke 20020101

• Investigation into the efficacy of bezafibrate against primary biliary cirrhosis, with histological references from cases receiving long term monotherapy.

  The American journal of gastroenterology 20020101

• Use of fibrates in the management of hyperlipidemia in HIV-infected patients receiving HAART.

  Infection 20020101

• Lipid-lowering drugs: are adverse effects predictable and reversible?

  Cardiology 20020101

• Mass spectrometric monitoring of the degradation and elimination efficiency for hardly eliminable and hardly biodegradable polar compounds by membrane bioreactors.

  Water science and technology : a journal of the International Association on Water Pollution Research 20020101

• The role of apoptotic regulators in metaplastic mucous cells.

  Novartis Foundation symposium 20020101

• Bioavailability study of tablet Bezafibrate 200 mg (Lipocor).

  Pakistan journal of pharmaceutical sciences 20020101

• 15-Deoxy-delta 12,14-prostaglandin J2 and thiazolidinediones activate the MEK/ERK pathway through phosphatidylinositol 3-kinase in vascular smooth muscle cells.

  The Journal of biological chemistry 20011228

• Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S.

  Circulation 20011218

• Blood lipids and first-ever ischemic stroke/transient ischemic attack in the Bezafibrate Infarction Prevention (BIP) Registry: high triglycerides constitute an independent risk factor.

  Circulation 20011211

• Alterations in the extrinsic pathway in hypertriglyceridemia do not cause a 'procoagulant state': effects of bezafibrate therapy.

  Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 20011201

• Lipid-lowering trials in diabetes.

  Current opinion in lipidology 20011201

• Alternations in hepatic expression of fatty-acid metabolizing enzymes in ArKO mice and their reversal by the treatment with 17beta-estradiol or a peroxisome proliferator.

  The Journal of steroid biochemistry and molecular biology 20011201

• Squalene synthase inhibitors reduce plasma triglyceride through a low-density lipoprotein receptor-independent mechanism.

  European journal of pharmacology 20011123

• A novel series of 2,6,7-substituted 2,3-dihydro-1,4-benzodioxin and 2,6,7-substituted 1,4-benzodioxin derivatives as lipid peroxidation inhibitors. Structure-activity relationships for high inhibition of human low-density lipoprotein peroxidation.

  Journal of medicinal chemistry 20011108

• High and low oxygen affinity conformations of T state hemoglobin.

  Protein science : a publication of the Protein Society 20011101

• Antecedent hyperglycemia, not hyperlipidemia, is associated with increased islet triacylglycerol content and decreased insulin gene mRNA level in Zucker diabetic fatty rats.

  Diabetes 20011101

• Are high density lipoprotein (HDL) and triglyceride levels relevant in stroke prevention?

  Cardiovascular research 20011101

• A prospective study of plasma fibrinogen levels and the risk of stroke among participants in the bezafibrate infarction prevention study.

  The American journal of medicine 20011015

• Antineoplastic and anti-inflammatory effects of PPAR ligands in colitis.

  Gastroenterology 20011001

• Variation at position 162 of peroxisome proliferator-activated receptor alpha does not influence the effect of fibrates on cholesterol or triacylglycerol concentrations in hyperlipidaemic subjects.

  Pharmacogenetics 20011001

• Changes in matrix proteoglycans induced by insulin and fatty acids in hepatic cells may contribute to dyslipidemia of insulin resistance.

  Diabetes 20010901

• Effects of bezafibrate on beta-cell function of rat pancreatic islets.

  European journal of pharmacology 20010831

• Concurrent administration of sustained-release bezafibrate may counteract the increased thrombotic risk associated with oral estrogen therapy.

  Medical hypotheses 20010801

• Bezafibrate reduces mRNA levels of adipocyte markers and increases fatty acid oxidation in primary culture of adipocytes.

  Diabetes 20010801

• Improvement in endothelial dysfunction in patients with hypoalphalipoproteinemia and coronary artery disease treated with bezafibrate.

  Journal of cardiovascular pharmacology 20010801

• Rhabdomyolysis and acute renal failure following a switchover of therapy between two fibric acid derivatives.

  Singapore medical journal 20010801

• Is pseudocholinesterase activity related to markers of triacylglycerol synthesis in Type II diabetes mellitus?

  Clinical science (London, England : 1979) 20010701

• Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease.

  Kidney international 20010701

• Fibrate-induced increase in blood urea and creatinine.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20010701

• Normocholesterolaemic dysslipidaemia: is there a role for fibrates?

  The Medical journal of Australia 20010604

• Three-dimensional high voltage electron microscopy of thick biological specimens.

  Micron (Oxford, England : 1993) 20010601

• Effect of bezafibrate in primary biliary cirrhosis: a pilot study.

  Liver 20010601

• Long-term diuretic therapy in patients with coronary disease: increased colon cancer-related mortality over a 5-year follow-up.

  Journal of human hypertension 20010601

• Effects of bezafibrate and simvastatin on plasma lipoproteins in hypercholesterolemia resistant to hormone replacement therapy.

  Maturitas 20010530

• Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate.

  Clinical pharmacology and therapeutics 20010501

• Study of effectiveness of bezafibrate in the treatment of chronic hepatitis C.

  The American journal of gastroenterology 20010501

• How is the liver primed or sensitized for alcoholic liver disease?

  Alcoholism, clinical and experimental research 20010501

• Differential involvement of peroxisome-proliferator-activated receptors alpha and delta in fibrate and fatty-acid-mediated inductions of the gene encoding liver fatty-acid-binding protein in the liver and the small intestine.

  The Biochemical journal 20010415

• Differential regulation of expression of genes encoding uncoupling proteins 2 and 3 in brown adipose tissue during lactation in mice.

  The Biochemical journal 20010401

• Chitotriosidase genotype and serum activity in subjects with combined hyperlipidemia: effect of the lipid-lowering agents, atorvastatin and bezafibrate.

  Metabolism: clinical and experimental 20010401

• Effects of bezafibrate on insulin sensitivity and insulin secretion in non-obese Japanese type 2 diabetic patients.

  Metabolism: clinical and experimental 20010401

• Effect of bezafibrate on soluble adhesion molecules and platelet activation markers in patients with connective tissue diseases and secondary hyperlipidemia.

  Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 20010401

• Antihypertensive mechanisms of lipid-lowering drugs: decoding the Rosetta stone's inscriptions'.

  Journal of hypertension 20010401

• Bezafibrate reduces heart rate and blood pressure in patients with hypertriglyceridemia.

  Journal of hypertension 20010401

• Homocysteine elevation with fibrates: is it a class effect?

  The Israel Medical Association journal : IMAJ 20010401

• Effect of bezafibrate and clofibrate on the heme-iron geometry of ferrous nitrosylated heme-human serum albumin: an EPR study.

  Journal of inorganic biochemistry 20010401

• Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate.

  The Journal of infection 20010401

• Ligands for peroxisome proliferator-activated receptors alpha and gamma inhibit chemically induced colitis and formation of aberrant crypt foci in rats.

  Cancer research 20010315

• Bezafibrate attenuates the overexpression of plasminogen activator inhibitor-1 messenger RNA by a combination of mono-unsaturated fatty acid and insulin in hepG2 cells.

  Life sciences 20010309

• Coronary artery reactivity after treatment with simvastatin.

  Current atherosclerosis reports 20010301

• Diabetes and lipids - a conundrum.

  Diabetic medicine : a journal of the British Diabetic Association 20010301

• [BECAIT [Bezafibrate Coronary Atherosclerosis Intervention Trial]].

  Nihon rinsho. Japanese journal of clinical medicine 20010301

• [Drug combination therapies for patients with hyperlipidemia and its significance].

  Nihon rinsho. Japanese journal of clinical medicine 20010301

• [Overviews of fibrate].

  Nihon rinsho. Japanese journal of clinical medicine 20010301

• [Drug interactions of lipid-lowering drugs and precaution of clinical use].

  Nihon rinsho. Japanese journal of clinical medicine 20010301

• Effect of a pharmacological activation of PPAR on the expression of RAR and TR in rat liver.

  Journal of physiology and biochemistry 20010301

• Effect of a pharmacological activation of PPAR on the expression of RAR and TR in rat liver.

  Journal of physiology and biochemistry 20010301

• Determination of drug residues in water by the combination of liquid chromatography or capillary electrophoresis with electrospray mass spectrometry.

  Journal of chromatography. A 20010223

• Differential induction of stearoyl-CoA desaturase and acyl-CoA oxidase genes by fibrates in HepG2 cells.

  Biochemical pharmacology 20010201

• Oral antidiabetic treatment in patients with coronary disease: time-related increased mortality on combined glyburide/metformin therapy over a 7.7-year follow-up.

  Clinical cardiology 20010201

• Normocholesterolaemic dyslipidaemia: is there a role for fibrates?

  The Medical journal of Australia 20010115

• Abundant expression of uncoupling protein-2 in the small intestine: up-regulation by dietary fish oil and fibrates.

  Biochimica et biophysica acta 20010115

• Statins in children: what do we know and what do we need to do?

  Current atherosclerosis reports 20010101

• The role of fibric acids in atherosclerosis.

  Current atherosclerosis reports 20010101

• The ligands/activators for peroxisome proliferator-activated receptor alpha (PPARalpha) and PPARgamma increase Cu2+,Zn2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells.

  Metabolism: clinical and experimental 20010101

• Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT Study)--a rebuttal.

  Thrombosis and haemostasis 20010101

• Bezafibrate induces acyl-CoA oxidase mRNA levels and fatty acid peroxisomal beta-oxidation in rat white adipose tissue.

  Molecular and cellular biochemistry 20010101

• Bezafibrate-induced anaphylactic shock: unusual clinical presentation.

  Journal of investigational allergology & clinical immunology 20010101

• Treating dyslipidaemia in non-insulin-dependent diabetes mellitus -- a special reference to statins.

  Journal of diabetes and its complications 20010101

• Effects of diet, drugs, and genes on plasma fibrinogen levels.

  Annals of the New York Academy of Sciences 20010101

• [Rhabdomyolysis and acute renal failure secondary to statins].

  Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20010101

• [Clinical, epidemiologic, and biochemical findings on the reverse cholesterol transport (cholesterol-HDL)].

  Bulletin de l'Academie nationale de medecine 20010101

• [Fibrates in the secondary prevention of ischemic cardiopathy].

  Archivos de cardiologia de Mexico 20010101

• Noninvolvement of hypertriglyceridemia and hyperleptinemia in blood pressure increases induced by dietary lard in rats.

  Drugs under experimental and clinical research 20010101

• Hypertriglyceridemia: associated risks and effect of drug treatment.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20010101

• Toremifene-induced fatty liver and NASH in breast cancer patients with breast-conservation treatment.

  International journal of oncology 20001201

• Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20001201

• The hypolipidemic action of bezafibrate therapy in hypertriglyceridemia is mediated by upregulation of lipoprotein lipase: no effects on VLDL substrate affinity to lipolysis or LDL receptor binding.

  Atherosclerosis 20001201

• Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone.

  Biochemical and biophysical research communications 20001130

• Down-regulation of uncoupling protein-3 and -2 by thiazolidinediones in C2C12 myotubes.

  FEBS letters 20001027

• A paradoxical severe decrease in serum HDL-cholesterol after treatment with a fibrate.

  Journal of clinical pathology 20001001

• [Marked creatine-phosphokinase elevation in myopathy after treatment with bezafibrate].

  Harefuah 20000901

• Peroxisome proliferator-activated receptor alpha (PPARalpha) activators, bezafibrate and Wy-14,643, increase uncoupling protein-3 mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes.

  Archives of biochemistry and biophysics 20000815

• Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease.

  Circulation 20000704

• Impaired expression of the uncoupling protein-3 gene in skeletal muscle during lactation: fibrates and troglitazone reverse lactation-induced downregulation of the uncoupling protein-3 gene.

  Diabetes 20000701

• Stimulation by eicosapentaenoic acids of leptin mRNA expression and its secretion in mouse 3T3-L1 adipocytes in vitro.

  Biochemical and biophysical research communications 20000413

• Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Fluvastatin Alone and in Combination Treatment.

  Thrombosis and haemostasis 20000401

• Serum insulin-like growth factor-I level is independently associated with coronary artery disease progression in young male survivors of myocardial infarction: beneficial effects of bezafibrate treatment.

  Journal of the American College of Cardiology 20000301

• Bezafibrate reduces blood glucose in type 2 diabetes mellitus.

  Metabolism: clinical and experimental 20000301

• The PPARs: from orphan receptors to drug discovery.

  Journal of medicinal chemistry 20000224

• Pravastatin compared to bezafibrate in the treatment of dyslipidemia in insulin-treated patients with type 2 diabetes mellitus.

  Diabetes/metabolism research and reviews 20000101

• Peroxisome proliferator-activated receptor beta regulates acyl-CoA synthetase 2 in reaggregated rat brain cell cultures.

  The Journal of biological chemistry 19991210

• Fibrates, dyslipoproteinaemia and cardiovascular disease.

  Current opinion in lipidology 19991201

• A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPARalpha agonist with potent lipid-lowering activity.

  Journal of medicinal chemistry 19990923

• Uncoupling protein-3 mRNA levels are increased in white adipose tissue and skeletal muscle of bezafibrate-treated rats.

  Biochemical and biophysical research communications 19990705

• Activators of peroxisome proliferator-activated receptor-alpha induce the expression of the uncoupling protein-3 gene in skeletal muscle: a potential mechanism for the lipid intake-dependent activation of uncoupling protein-3 gene expression at birth.

  Diabetes 19990601

• Effects of fibrate compounds on expression of plasminogen activator inhibitor-1 by cultured endothelial cells.

  Arteriosclerosis, thrombosis, and vascular biology 19990601

• Statin + fibrate combination therapy fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease.

  International journal of cardiology 19990601

• Combined effects of probucol and benzafibrate on lipoprotein metabolism and liver cholesteryl ester transfer protein mRNA in cholesterol-fed rabbits.

  Japanese circulation journal 19990601

• Bezafibrate for tamoxifen-induced non-alcoholic steatohepatitis.

  Lancet (London, England) 19990522

• Phytanic acid is ligand and transcriptional activator of murine liver fatty acid binding protein.

  Journal of lipid research 19990401

• BM 17.0744: a structurally new antidiabetic compound with insulin-sensitizing and lipid-lowering activity.

  Metabolism: clinical and experimental 19990101

• Effect of lipoprotein lipase activators bezafibrate and NO-1886, on B16 melanoma-induced cachexia in mice.

  Anticancer research 19990101

• A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma: effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats.

  Diabetes 19981201

• Fibrate-modulated expression of fibrinogen, plasminogen activator inhibitor-1 and apolipoprotein A-I in cultured cynomolgus monkey hepatocytes -- role of the peroxisome proliferator-activated receptor-alpha.

  Thrombosis and haemostasis 19981201

• Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT).

  Journal of the American College of Cardiology 19981115

• Results of the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and an update on trials now in progress.

  European heart journal 19980701

• Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia.

  Atherosclerosis 19980501

• Effect of hypolipidemic drugs on key enzyme activities related to lipid metabolism in normolipidemic rabbits.

  European journal of pharmacology 19980424

• Clinical pharmacokinetics of fibric acid derivatives (fibrates).

  Clinical pharmacokinetics 19980201

• Bezafibrate has an antioxidant effect: peroxisome proliferator-activated receptor alpha is associated with Cu2+, Zn2+-superoxide dismutase in the liver.

  Life sciences 19980101

• Effect of bezafibrate treatment over five years on coronary plaques causing 20% to 50% diameter narrowing (The Bezafibrate Coronary Atherosclerosis Intervention Trial [BECAIT]).

  The American journal of cardiology 19971101

• Comparison of bezafibrate and simvastatin in the treatment of dyslipidaemia in patients with NIDDM.

  Diabetic medicine : a journal of the British Diabetic Association 19970701

• Retardation of coronary atherosclerosis: the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and other angiographic trials.

  Cardiovascular drugs and therapy 19970501

• Improved insulin sensitivity by bezafibrate in rats: relationship to fatty acid composition of skeletal-muscle triglycerides.

  Diabetes 19970301

• Improved glucose tolerance after effective lipid-lowering therapy with bezafibrate in a patient with lipoatrophic diabetes mellitus: a putative role for Randle's cycle in its pathogenesis?

  Clinical endocrinology 19970301

• Hepatic microsomal enzyme induction, beta-oxidation, and cell proliferation following administration of clofibrate, gemfibrozil, or bezafibrate in the CD rat.

  Toxicology and applied pharmacology 19970101

• Studies on the mechanism of fibrate-inhibited expression of plasminogen activator inhibitor-1 in cultured hepatocytes from cynomolgus monkey.

  Arteriosclerosis, thrombosis, and vascular biology 19970101

• Post-prandial metabolism of triglyceride-rich lipoproteins in non-insulin-dependent diabetic patients before and after bezafibrate treatment.

  European journal of clinical investigation 19970101

• A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia.

  Cardiovascular drugs and therapy 19970101

• Opposite effects of bezafibrate and gemfibrozil in both normal and hypertriglyceridemic rats.

  Atherosclerosis 19961115

• The role of phosphatidylethanolamine methylation in the secretion of very low density lipoproteins by cultured rat hepatocytes: rapid inhibition of phosphatidylethanolamine methylation by bezafibrate increases the density of apolipoprotein B48-containing lipoproteins.

  Biochimica et biophysica acta 19961111

• Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia.

  Drugs 19961101

• Effect of fluvastatin or bezafibrate on the distribution of high density lipoprotein subpopulations in patients with familial hypercholesterolemia.

  Arzneimittel-Forschung 19960901

• Growth regulation by peroxisome proliferators: opposing activities in early and late G1.

  Cancer research 19960715

• Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients.

  Lancet (London, England) 19960330

• L-lactate dehydrogenase A4- and A3B isoforms are bona fide peroxisomal enzymes in rat liver. Evidence for involvement in intraperoxisomal NADH reoxidation.

  The Journal of biological chemistry 19960216

• Fluvastatin in combination with other lipid-lowering agents.

  British journal of clinical practice. Supplement 19960101

• Effect of troglitazone (CS-045) and bezafibrate on glucose tolerance, liver glycogen synthase activity, and beta-oxidation in fructose-fed rats.

  Metabolism: clinical and experimental 19951201

• Rhabdomyolysis and acute renal failure associated with bezafibrate treatment.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 19951201

• Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: a potential physiologic basis for their mode of action.

  Journal of lipid research 19951201

• Currently available hypolipidaemic drugs and future therapeutic developments.

  Bailliere's clinical endocrinology and metabolism 19951001

• Efficacy and safety of triple therapy (fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia.

  The American journal of cardiology 19950713

• Selective modification of rat hepatic microsomal fatty acid chain elongation and desaturation by fibrates: relationship with peroxisome proliferation.

  British journal of pharmacology 19950401

• Bezafibrate induced reduction of renal function in a renal transplant recipient.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 19950101

• Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element.

  The Journal of biological chemistry 19941209

• Fluvastatin in combination with other lipid-lowering agents.

  British journal of clinical practice. Supplement 19941201

• The effects of clofibrate and bezafibrate on cholesterol metabolism in the liver of the male rat.

  Lipids 19941101

• Effect of bezafibrate on lipids, lipoproteins, apolipoproteins and platelet aggregation in hypertriglyceridemic patients.

  Arzneimittel-Forschung 19941101

• Peripheral neuropathy with bezafibrate.

  BMJ (Clinical research ed.) 19941008

• Treatment of primary hypercholesterolemia: fluvastatin versus bezafibrate.

  The American journal of medicine 19940606

• Efficacy and safety of a combination fluvastatin-bezafibrate treatment for familial hypercholesterolemia: comparative analysis with a fluvastatin-cholestyramine combination.

  The American journal of medicine 19940501

• Localization of carnitine acetyltransferase activity in brown adipocytes of the rat.

  The Journal of veterinary medical science 19940401

• Effects of treatment with bezafibrate on lipoprotein lipase activity and mass in patients with hypertriglyceridemia.

  Arzneimittel-Forschung 19940201

• A recombinant phenobarbital-inducible rat liver UDP-glucuronosyltransferase (UDP-glucuronosyltransferase 2B1) stably expressed in V79 cells catalyzes the glucuronidation of morphine, phenols, and carboxylic acids.

  Molecular pharmacology 19940101

• Regulation of xanthine dehydrogenase in rat liver in response to peroxisome proliferators.

  Biochemical and biophysical research communications 19930915

• The effect of bezafibrate treatment on serum alkaline phosphatase isoenzyme activities.

  Metabolism: clinical and experimental 19930701

• Severe reversible renal failure with bezafibrate.

  Lancet (London, England) 19930206

• Bezafibrate-induced myopathy: no evidence for defects in muscle metabolism.

  European neurology 19930101

• Mechanism of action of fibrates.

  Postgraduate medical journal 19930101

• [Bezafibrate myopathy in two patients with chronic renal failure].

  Rinsho shinkeigaku = Clinical neurology 19920701

• Effect of bezafibrate on lipoprotein (a) and triglyceride-rich lipoproteins, including intermediate-density lipoproteins, in patients with chronic renal failure receiving haemodialysis.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 19920101

• The role of NADPH in the regulation of glucose-6-phosphate and 6-phosphogluconate dehydrogenases in rat adipose tissue.

  Molecular and cellular biochemistry 19910626

• [Bezafibrate-induced necrotizing myopathy].

  Medicina clinica 19910323

• Effects of bezafibrate on hepatic cholesterol metabolism.

  European journal of clinical pharmacology 19910101

• Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteins.

  Journal of clinical pharmacology 19910101

• [A case of acute rhabdomyolysis and acute renal insufficiency caused by the simultaneous use of furosemide and bezafibrate].

  Minerva medica 19901201

• The induction of adipose conversion by bezafibrate in 3T3-L1 cells. Synergism with dibutyryl-cAMP.

  Biochimica et biophysica acta 19900901

• Lowering of plasma glucose concentrations with bezafibrate in patients with moderately controlled NIDDM.

  Diabetes care 19900801

• Long-term effects of peroxisome proliferators on the balance between hydrogen peroxide-generating and scavenging capacities in the liver of Fischer-344 rats.

  Toxicology 19900801

• Interruption of long-term lipid-lowering treatment with bezafibrate in hypertriglyceridaemic patients. Effects on lipoprotein composition, lipase activities and the plasma lipid fatty acid spectrum.

  Atherosclerosis 19900501

• Induction of fatty acid binding protein by peroxisome proliferators in primary hepatocyte cultures and its relationship to the induction of peroxisomal beta-oxidation.

  Biochimica et biophysica acta 19900423

• Sustained-release bezafibrate corrects lipid abnormalities in patients on continuous ambulatory peritoneal dialysis.

  Nephron 19900101

• [A case of hepatitis caused by exifone and bezafibrate].

  Gastroenterologie clinique et biologique 19890401

• [Acute severe myositis due to bezafibrate treatment].

  Harefuah 19890301

• Effect of combined therapy with bezafibrate and cholestyramine on low-density lipoprotein metabolism in type IIa hypercholesterolemia.

  Metabolism: clinical and experimental 19890201

• Effects of bezafibrate on insulin secretion and peripheral insulin sensitivity in hyperlipidemic patients with and without diabetes.

  Atherosclerosis 19890201

• Bezafibrate-induced headache.

  Lancet (London, England) 19890121

• Treatment of heterozygous familial hypercholesterolemia with lipid-lowering drugs.

  Arteriosclerosis (Dallas, Tex.) 19890101

• [Pharmacological investigation of bezafibrate, a hypolipidemic agent (2). Mechanism of the hypolipidemic action of bezafibrate in rats].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 19880901

• Interactions of inhibitors of carnitine palmitoyltransferase I and fibrates in cultured hepatocytes.

  The Biochemical journal 19880701

• [Bezafibrate-induced myoglobinuric kidney failure in a 54-year-old patient with diabetes mellitus type IIa].

  Medizinische Klinik (Munich, Germany : 1983) 19880304

• Bezafibrate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidaemia.

  Drugs 19870601

• Biliary lipid secretion in patients with heterozygous familial hypercholesterolemia and combined hyperlipidemia. Influence of bezafibrate and fenofibrate.

  Journal of lipid research 19860701

• Change in very low-, low-, and high-density lipoproteins during lipid lowering (bezafibrate) therapy: studies in type IIA and type IIb hyperlipoproteinaemia.

  European journal of clinical investigation 19860201

• Effect of bezafibrate on plasma lipids, lipoproteins, apolipoproteins AI, AII and B and LCAT activity in hyperlipidemic, non-insulin-dependent diabetics.

  Atherosclerosis 19820601

• [Drug treatment of hyperlipoproteinemias].

  Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete 19770501